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With valuable inspirations from them and full support from Mikael R. Andersen (Associated 
Professor at DTU) and Dietmar Weilguny (Principal Scientist at Symphgen), who later on became 
my main supervisors of PhD study, a grant application of industrial PhD were submitted to and later 
on approved by Danish Agency for Science, Technology and Innovation. I would like to address my 
sincere gratitude to all these people for making the industrial PhD project financially possible. 
I would like to express my deepest acknowledgements for the comprehensive guidance and solid 
help I received from my supervisor team, including Mikael R. Andersen and Dietmar Weilguny as 
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supervisors. In particular, I would like to thank Mikael and Dietmar who conveyed a great 
enthusiasm and provided an excellent supervision for me along the whole project. Their optimistic 
spirit, constructive suggestion, innovative inspiration and endless support make me, a humble 
student gradually become a confident scientist. I am also especially grateful to Christian, who has 
shown a genuine interest in me and always has willingness to help me in problem solving.  
Through Christian, I was put in touch with two excellent researchers in glycosylation modeling 
from Imperial College London, UK, Ioscani Jimenez Del Val (former Postdoc at Imperial College) 
and Cleo Kontoravdi (Lecture at Imperial College), who showed a great hospitality during my visit 
to their research group. More importantly, they both had great passions and provided tremendous 
contributions to our collaborative projects. It is such a good luck to find the two personally and 
scientifically nice collaborators. I sincerely hope that we can continue our collaborations on other 
projects in the future. 
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Summary 
Thanks to the recent advances in Chinese hamster ovary (CHO) “omic” revolution, the development 
of recombinant therapeutic protein bioprocessing using CHO cell factory started to merge with the 
new biological mindset called systems biology. In order to produce a CHO-derived recombinant 
therapeutic protein with ensured safety, efficacy and cost-effectiveness, holistic understanding of 
titer and N-glycosylation of the protein in relation to cell culture process as well as genomic, 
proteomic, metabolic and physiological status of the cells becomes a superior approach. Combining 
the knowledge of CHO cell culture technology, upstream process engineering, metabolic 
engineering, and glycobiology into a systematic framework allow us to improve the production of 
recombinant therapeutic protein towards an optimal balance between quantity and quality.  
In the presented work, recent know-how on impact, analysis, control and optimization of N-
glycosylation were thoroughly reviewed. In particular, how to control and optimize N-glycosylation 
in CHO cells was exclusively studied. The main focus of this PhD project is to find effective 
approaches of modulating N-glycosylation of CHO-derived recombinant monoclonal antibody 
(mAb) towards desired patterns, and at the same time try to understand the underlying mechanisms 
of that from a systems biology perspective. Two different strategies were used and achieved great 
success in glyco-optimization: 1) optimize media and culture process; 2) Genetically optimize CHO 
cell factory. 
In the early part of the thesis, the first strategy was displayed by a number of successful case studies, 
in which process and media engineering approach was successfully used to direct N-glycosylation. 
Controlling the balance between glucose and amino acid metabolism, using galactose as feed 
additives, changing process parameters such as seeding density and cultivation duration are all 
demonstrated to be effective. The causal explanation of their impact on glycosylation can be various, 
including product, metabolism, proteome and physiology-associated mechanism. 
In the middle part of the thesis, both literature reviews and experimental applications were provided 
to demonstrate how to use omics data and implement systems biology to understand biological 
activities, especially N-glycosylation in CHO cells. 
In the last part of the thesis, the second strategy that apply genetic and metabolic engineering 
approach to improve N-glycosylation capability of CHO cells was also presented promising results. 
Overexpression of either N-acetylglucosaminyltransferase I (GnTI) in CHO cells was confirmed to 
improve the maturation of glycans in mAb. 
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In conclusion, integrating the concept of systems biology with process and metabolic engineering 
has been demonstrated through a number of studies to be a superior way of controlling and 
optimizing N-glycosylation of CHO-derived recombinant therapeutic protein. 
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Resumé 
Takket være nylige fremskridt inden for den "omic" revolution af Chinese hamster ovary (CHO) 
celler, er udvikling og produktion af rekombinante terapeutiske proteiner i CHO cellefabrikker 
begyndt at blive præget med afsæt i systembiologi. En holistisk forståelse af titer og N-
glykosylering af et produceret rekombinant protein i forhold til den tilknyttede celle kultiverings 
proces, samt en genomisk, proteomisk, metabolisk og fysiologisk forståelse, vise sig at være yderst 
effektiv når der samtidig er fokus på sikkerhed, effektivitet og pris, af det enkelte protein. Ved at 
kombinere og sammensætte viden indenfor CHO celle kultiverings teknologi, upstream proces 
udvikling, metabolisk optimering, og glyco-biologi, til et systematisk framework med fokus på 
kvalitet og kvantitet, kan produktionen af rekombinante terapeutiske proteiner blive optimeret. 
I det præsenterede arbejde er det seneste know-how indenfor analyse, kontrol og optimering af N-
glykosylering, samt indflydelsen af N-glykosylering på terapeutiske proteiner, blevet grundigt 
revideret og analyseret. Mere specifikt er det blevet undersøgt hvordan man kan kontrollere og 
optimere N-glykosylering i CHO celler. Hoved fokus i dette PhD projekt har været at udvikle 
effektive metoder til modelering af N-glycosylering af CHO-producerede recombinante 
monoklonale antistoffer (mAb), således at ønskede glycosylerings mønstre kan opnåes, samtidig 
med at udvide forståelsen for de dybere mekanismer der styrer N-glycosylering set fra et 
systembiologisk perspektiv. To forskellige strategier blev brugt til at glyko-optimere med stor 
succes: 1) optimering af medie og kultiverings processer; 2) genetisk forbedring af CHO som 
cellefabrik. 
I den første del af tesen, er den første strategi demonstreret af flere successfulde case-studies, hvor 
process- og medieoptimering blev brugt til at styre N-glykosyleringen. Balancen mellem glukose- 
og aminosyremetabolismen blev kontrolleret ved at bruge galaktose som feed additiv og ved at 
ændre process parametre såsom udsåningstætheden og længden af kultiveringen. Ved at kontrollere 
balancen mellem glukose- og aminosyremetabolismen, kunne N-glycosyleringen påvirkes. Der er 
flere forklaringer på, hvorfor denne balance styrer glykosyleringen, herunder mekanismer associeret 
med produktion, metabolisme, proteomet, og fysiologi. 
I den anden del af tesen bliver både literaturen og eksperimentelle applikationer undersøgt, for at 
demonstrere hvorledes omics data og implementering af systembiologi kan udnyttes til at forstår 
biologiske mekanismer, herunder N-glycosylering i CHO celler. 
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I den tredje og sidste del af tesen, bliver den anden strategi demonstreret. Lovende resultater viser at 
det er muligt at optimere N-glykosylering ved at modificere genetikken og metabolismen i CHO 
celler. Ved at overudtrykke enten N-acetylglucosaminyltransferase I (GnTI) proteiner kunne 
GlcNAc tilgængeligheden øges, med en medfølgende forbedring af matureringen af glykaner i 
mAbs. 
Resultaterne demonstrerer integrationen af systembiologi koncepter og process- og metabolisme 
modifikationer, som en effektiv måde hvorved N-glykosylering af CHO-producerede rekombinante 
terapeutiske proteiner kan kontrolleres og optimeres. 
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Chapter 1 Introduction 
This PhD thesis present the work carried from January 2012 to December 2014 under my industrial 
PhD study. The study has been co-financed by an industrial PhD grant from Danish Agency for 
Science, Technology and Innovation and Symphogen A/S. The study was performed in 
collaboration between the research group Network Engineering of Eukaryotic Cell Factories, 
Department of Systems Biology, Technical University of Denmark and Symphogen A/S.  Some of 
the work also involved international collaboration partners from Center for Process Systems 
Engineering, Department of Chemical Engineering, Imperial College London and Department of 
Chemical and Biomolecular Engineering, Johns Hopkins University.  
The aim of this thesis is to investigate different possibilities to direct monoclonal antibody (mAb) 
N-glycosylation in Chinese hamster ovary (CHO) cells towards more desired patterns, and at the 
same time, to analyze and understand the genetic features, metabolic networks, and physiological 
properties of the cells that control the process of N-glycosylation. In this thesis, metabolic 
engineering of CHO cells via both process and genetic manipulations to optimize mAb 
glycosylation were studied. Many valuable understandings concerning impact, control and 
improvement of mAb glycosylation were discussed.  
The thesis contains a collection of published articles and unpublished manuscripts, which provide 
both literature reviews with up-to-date knowledge in this field and a number of study cases 
reflecting industrial applications of the results.  
1.1. Structure of the thesis 
Chapter 2 provides general background knowledge to this work by presenting a review of the 
impact of glycosylation on mAb properties and the techniques used for accessing protein 
glycosylation. Furthermore, to provide status and relevant industrial application in this research 
field, the chapter also presents a review of process and genetic engineering on N-glycosylation of 
recombinant proteins. This work has been written as Fan Y, Weilguny D, Andersen MR. 
Glycosylation: impact, analysis and control in biopharmaceuticals (Manuscript in Preparation). 
Chapter 3 presents a study case of changing antibody production and glycosylation by controlling 
amino acid and glucose metabolism in CHO cell fed-batch process. The work provides a 
comprehensive understanding of glycosylation in CHO cells from metabolic perspectives. The 
content of this chapter has been published in Biotechnology and Bioengineering: Fan Y, Jimenez 
Del Val I, Müller C, Wagtberg Sen J, Rasmussen SK, Kontoravdi C, Weilguny D, Andersen MR. 
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Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and 
glycosylation. Biotechnology and Bioengineering, 2014 (DOI: http://dx.doi.org/10.1002/bit.25450). 
Chapter 4 presents another study case of glycosylation manipulation through process engineering, 
in which impact on N-glycosylation by addition of different feed additives that are expected to 
involved in nucleotide sugars (NSs) synthesis pathway were investigated. This work has been 
drafted as Kildegaard HF, Fan Y, Wagtberg Sen J, Larsen B, and Andersen MR. Glycoprofiling the 
effect of media additives on IgG produced by CHO cells in fed-batch bioreactors (Shared first 
author; Manuscript in Preparation). 
Chapter 5 provides a review of systems biology and genome-scale modeling that has been reported 
in CHO cells. The application of omics data in generating computational models for predictive and 
descriptive analysis of CHO cellular metabolism and in providing perspectives for protein 
production was described. This work has been published as Kaas CS, Fan Y, Weilguny D, 
Kristensen C, Kildegaard HF, Andersen MR. Towards genome-scale-models of the Chinese 
hamster ovary cells: incentives, status, and perspectives. Pharmaceutical Bioprocessing, 2014, 2 (5). 
Chapter 6, a study case of applying the concepts from Chapter 5, describes an approach for 
understanding mAb glycosylation using systems-biology based analysis including metabolic and 
proteomic data in order to find the suitable operation window of some traditional critical process 
parameters. This work has been submitted to Biotechnology and Bioengineering as Fan Y, Jimenez 
Del Val I, Müller C, Lund AM, Wagtberg Sen J, Rasmussen SK, Kontoravdi C, Betenbaugh MJ, 
Weilguny D, Andersen MR. Systems-based investigation into the effect of glucose starvation and 
culture duration on fed-batch CHO cell culture (Submitted). 
Chapter 7 describes a case of glyco-optimization via genetic engineering approach in CHO cells. 
In this study, two key enzymes involved in glycosylation processing were overexpressed in 
engineered cell lines. The effect of that was studied from glycomic and metabolic points of view. 
This work has been described in Fan Y, Jimenez Del Val I, Müller C, Wagtberg Sen J, Rasmussen 
SK, Kontoravdi C, Betenbaugh MJ, Weilguny D, Andersen MR. Chinese hamster ovary cell 
engineering to improve the maturation of recombinant monoclonal antibody N-glycosylation 
(Manuscript in Preparation). 
Finally, Chapter 8 contains conclusions and perspectives of the obtained results in this thesis.  
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Chapter 2 Glycosylation: impact and control in mAb 
production 
Yuzhou Fan
1, 2
, Dietmar Weilguny
2,*
, Mikael R. Andersen
1,*
 
1
Department of Systems Biology, Technical University of Denmark, Denmark 
2
Symphogen A/S, Ballerup, Denmark 
*Corresponding author.  
Address correspondence to Mikael Rørdam Andersen, Department of Systems Biology, Technical 
University of Denmark, Building 223, 2800 Kgs. Lyngby, Denmark; +4545252675; mr@bio.dtu.dk 
Address correspondence to Dietmar Weilguny, Cell line and Upstream, Symphogen A/S, 
Pederstrupvej 93, 2750 Ballerup, Denmark; +4588382683; dw@symphogen.com 
Biopharmaceuticals, also known as biologics, is a major source of medical innovation that opens up 
novel treatment possibilities in the future for many difficult-to-treat diseases. They are normally 
defined as non-chemically synthesized medicinal products, which manufactured by living 
organisms using biotechnology other than direct extract from a non-engineered biological source 
(Rader 2008). They are usually complex macromolecules consisting of proteins, sugars, 
nucleotides, lipids or their complex combinations, or even living cells and tissues. Until now, the 
majority of the marketed biopharmaceuticals are within the categories of recombinant vaccines and 
recombinant therapeutic proteins (Walsh 2014).  
In 2013, the market size of biopharmaceuticals increased up to 140 billion USD. Monoclonal 
antibodies (mAbs), in particular, which could target cancer, infectious disease, inflammatory and 
autoimmune conditions generate 63 billion USD in sales (Walsh 2014).  Mammalian cells will 
continue to dominant the expression platforms used for producing mAb for the immediate future, 
mainly because their adaptability in industrial application and capability of making appropriate N-
glycosylation of recombinant protein that is suitable for human (Butler 2006; Shi and Goudar 2014).  
Among mammalian-based expression systems, Chinese hamster ovary (CHO) cells remain as the 
most commonly used work-horse for mAb production (Walsh 2014).  
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Figure 1. N-glycosylation processing pathway. 
N-glycosylation profile is essential to ensure the physicochemical, biological and clinical properties 
of mAbs, including structure stability, solubility, serum half-life, effector function, efficacy, 
immunogenicity (Berger et al. 2012; Butler 2006; Costa et al. 2013) Consequently, the ability to 
monitor and control N-glycosylation becomes crucial in pharmaceutical bioprocessing as well as 
regulatory approval of mAb.  
N-glycosylation is taken place in endoplasmic reticulum (ER) and Golgi apparatus with several 
steps of catalytic reactions driven by a repertoire of glycotransferases, glycosidases (Figure 1). 
These reactions consist of attachment of lipid-linked oligosaccharide precursor (Glc3Man9GlcNAc2-
PP-dolichol) to N-glycosylation site (an Asn-X-Ser/Thr sequon) of protein in question, a series of 
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glucose and mannose residues removal reactions and a number of sugar residue addition reactions 
(e.g. addition of N-acetylglucosammine (GlcNAc), galactose, fucose and sialic acid residues using 
UDP-GlcNAc, UDP-Galactose, GDP-Fucose, and CMP-Sialic acid as the substrates). Detailed N-
glycosylation pathways have been described in the introduction section of Chapter 3.  
N-glycosylation patterns are known to be largely dependent on factors such as 3D structure of the 
recombinant protein (Butler 2006; Hills et al. 2001),  residence time in the Golgi, localizations and 
activities of the glycosylation processing enzymes (Ahn et al. 2008; Gawlitzek et al. 2000; Kodama 
et al. 1991; Pacis et al. 2011; Rivinoja et al. 2009; Schmelzer and Miller 2002), the availability of 
intracellular nucleotide sugar substrates (Barnabe and Butler 2000; Chee Furng Wong et al. 2005; 
Gramer et al. 2011; Hayter et al. 1992; Nyberg et al. 1999; Takuma et al. 2007; Wong et al. 2010b) 
and physiological condition of the protein processing machinery (Ahn et al. 2008; Senger and 
Karim 2003). A rapid growing exploration within this context is being conducted, with regard to (1) 
the impact of different glycoforms on the therapeutic properties of mAb, (2) the analytical 
techniques for accessing glycosylation information, (3) the influence of diverse process parameters, 
media and feed during the manufacturing process on mAb glycosylation, and (4) the strategies to 
engineer and optimize glycosylation to achieve better mAb quality.  
2.1. N-Glycosylation patterns can affect therapeutic protein properties 
Stability and solubility of biopharmaceuticals is the major concerns for the storage, formulation and 
clinical application of the product, which has been reported to be largely dependent on appropriate 
N-glycosylation including site occupancy, length, branch, charge and terminal sugar residues of the 
glycans attached (Raju and Scallon 2007; Reuter and Gabius 1999; Sola and Griebenow 2009; 
Wittwer and Howard 1990; Yamane-Ohnuki and Satoh 2009).  
Besides its physicochemical effects, glycosylation can also influence the therapeutic efficacy of the 
product (Table 2.1). First of all, serum half life has been shown to be mediated by structure of the 
glycans (Erbayraktar et al. 2003; Walsh and Jefferis 2006). In particular, terminal sugar residues of 
the glycans play a most important role in this property. Terminal mannose (Man) and GlcNAc, 
galactose (Gal) residues that have high affinity with various types of receptors in human may 
increase the clearance rate of the therapeutic protein (Jones et al. 2007; Wright et al. 2000). On the 
other hands, terminal N-acetylneuraminic acid (sialic acids, NANA) will increase the serum half 
life of the therapeutic protein (Egrie et al. 2003; Zhu 2012).  
Secondly, glycosylation of mAb can change the conformational structure of the fragment 
crystallizable (Fc) region and exert a critical impact on the effector function such as antibody-
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dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) by 
modulating the binding specificities and affinities to Fcγ receptors (a protein that can bind to Fc part 
of a IgG and can be found at the surface of different immune cells, for example B lymphocytes, 
natural killer cells and macrophages) and complement component C1q  (Crispin et al. 2009; Jefferis 
2009; Matsumiya et al. 2007; Raju 2008). Thirdly, galactose-α-1,3-galactose and N-
glycolylneraminic acid (NGNA) structures in glycans are known to be immunogenic to humans and 
CHO derived recombinant glycoproteins can bear small amount of this structures (Lammerts van 
Bueren et al. 2011; Macher and Galili 2008; Padler-Karavani et al. 2008). 
 
Table 2.1. List of reported impact of mAb glycosylation on their therapeutic efficacy 
Glycan structures Impact on mAb therapeutic efficacy References 
High Mannose 
 
Increased clearance rate; Enhanced 
ADCC; Reduced CDC; Increased 
immunogenicity 
(Goetze et al. 2011; Jones 
et al. 2007; Raju 2003; Shi 
and Goudar 2014; Zhou et 
al. 2008) 
Non-fucosylation 
 
Enhanced ADCC (Ferrara et al. 2006; Iida et 
al. 2006; Shinkawa et al. 
2003; Zhou et al. 2008) 
Bisecting GlcNAc 
 
Enhanced ADCC (Abes et al. 2010; Davies 
et al. 2001; Umana et al. 
1999) 
Terminal sialic acid 
 
Reduced clearance rate; Reduced 
ADCC 
(Anthony et al. 2008; 
Kaneko et al. 2006; 
Scallon et al. 2007; 
Sondermann et al. 2001) 
Terminal galactose 
 
Increased clearance rate; Enhanced 
CDC 
(Costa et al. 2013; 
Hodoniczky et al. 2005; 
Raju 2003; Shinkawa et al. 
2003) 
Terminal GlcNAC 
 
Increased clearance rate; Enhanced 
CDC 
(Jones et al. 2007; 
Malhotra et al. 1995; Raju 
2008) 
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Galactose-α-1, 3-galactose 
structure 
 
Highly immunogenic to human (Lammerts van Bueren et 
al. 2011; Macher and Galili 
2008) 
N-glycolylneuraminic acid 
(NGNA) structure 
 
Highly immunogenic to human (Berger et al. 2012; Padler-
Karavani et al. 2008) 
        
2.2. Analytical techniques for accessing glycosylation information 
Several techniques have been developed for accessing the glycosylation information from different 
aspects, in order to comprehensively understand and effectively control the process of glycosylation 
from following three levels: (1) the presence and structure of glycans; (2) the abundance of 
nucleotide sugars that are used as building blocks for the elongation of glycans; (3) the activity and 
expression of key enzymes for glycosylation processing such as nucleotide sugar synthetases and 
transporters, glycosyltransferases and glycosidases. 
2.2.1. Glycosylation analysis 
Glycosylation analysis can be done at the levels of glycoproteins, glycopeptides as well as glycans 
in order to measuring the degree of glycosylation. 
Analysis of intact glycoproteins and glycopeptides is typically an easy, cheap and fast approach 
with relatively low resolution. Different degrees of glycosylation such as site occupancy and level 
of glycan maturation can normally be obtained using this approach. Analytical methods for example 
SDS-PAGE (Liu et al. 2014; Osborne and Brooks 2006; Roth et al. 2012), cation exchange (CEX)-
based HPLC (Gaza-Bulseco et al. 2008; Yan et al. 2009) (Chapter 6) and LC-MS analysis 
(Dalpathado and Desaire 2008; Fan et al. 2014) can be used to separate the glycoprotein or 
glycopeptides based on their molecular weight, surface charge and mass, respectively.  
Glycan profiling, on the other hand, is a rather complicated, time-consuming and expensive 
approach, but is able to provide in-depth structural information of the glycans. This can be normally 
done by a fluorescent label based chromatographic method (Domann et al. 2007; Fan et al. 2014) or 
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a matrix-assisted laser desorption ionization (MALDI) or electrospray ionization (ESI) based mass 
spectrometry method (Marino et al. 2010; Roth et al. 2012).      
2.2.2. Nucleotide sugar analysis 
Nucleotide sugar analysis offers the possibility of accessing glycosylation at the substrate level of 
glycans. Analytical techniques including ion-pair reversed-phase high-performance liquid 
chromatography (IPRP HPLC) (Kochanowski et al. 2006; Nakajima et al. 2010; Rabina et al. 2001), 
high-performance ion-exchange chromatography (HPAEC) (Jimenez Del Val et al. 2013; Pels 
Rijcken et al. 1990; Tomiya et al. 2001), and capillary electrophoresis (Feng et al. 2008; Soo et al. 
2004) were developed.  Each method has its advantages and disadvantages in terms of analysis time, 
resolution and complexity in preparation for the analysis. IPRP HPLC, although is a relatively fast 
analysis (~30 min per sample), has always limitations in resolving certain species. HEAEC method, 
on the other hand, providing better resolution with few unresolved peaks, normally requires harsh 
buffer conditions (high pH) and long analysis time (> 50 min per sample). Additionally, capillary 
electrophoresis, a fast and high-resolution technique has some downsides of requiring laborious 
buffer preparation and sophisticated detection methods. 
2.2.3. Analysis of CHO glycosylation-related enzymes 
Since the maturation of glycans are supported and catalyzed by a series of enzymatic reaction, the 
expression of glycosylation-related enzymes is a key factor for monitoring glycosylation as well. In 
general, four different types of key enzymes have been considered in recent publications when 
investigating glycosylation: (1) Glycotransferases are responsible to transfer various sugar residues 
onto glycan chain using corresponding nucleotide sugars. (2) Glycosidases are the enzymes that can 
degrade glycans by trimming of specific sugar residues. (3) Nucleotide sugar synthetase drives the 
biosynthesis of nucleotide sugars, which are as building blocks for glycosylation. (4) Nucleotide 
sugar transporters that transport nucleotide sugars into ER and Golgi compartments and thus make 
them available for glycotransferases during the chain elongation reactions of glycan. Different 
analytical techniques for measuring the expression of CHO glycosylation-related enzymes have 
been reported. Several traditional approaches including quantitative real-time PCR (qRT-PCR) 
analysis (Chen and Harcum 2006; Clark et al. 2005; Pacis et al. 2011; Wong et al. 2010a), western 
blot analysis (Fan et al. 2014), and CHO glyco-gene microarray (Wong et al. 2010b) were 
successfully carried out and shown to be able to deliver accurate and reproducible results. In the 
light of the development of CHO genomics (Cao et al. 2012; Lewis et al. 2013; Xu et al. 2011), 
more advanced approaches became possible for glycosylation-related gene analysis in CHO, 
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including transcriptome and proteome analysis using RNA-sequencing (RNA-seq) (McGettigan 
2013) and the tandem mass spectrometry  (Baycin-Hizal et al. 2012), respectively.  
In parallel with the maturation of techniques measuring the expressions of glycosylation-related 
enzymes, functional assays that quantify the activities of these enzymes were also developed. To 
analyze the actives of glycosyltransferases, conventional radiochemical, immunological, 
phosphates-coupled and pH-based assays were existed (Palcic and Sujino 2001; Wagner and Pesnot 
2010; Wu et al. 2011), but all with limitation in the context of throughput. Recently, novel assays 
with the ability of high throughput screening of universal glycosyltransferases were developed in 
the light of the advance in sensor technology, for example fluorescent ATP sensor and 1-Zn(II) 
NDP sensor (Lee and Thorson 2011; Ryu et al. 2014). Regarding functional analysis of nucleotide 
sugar transporters, even though some impressive results have been reported (Hadley et al. 2014; 
Norambuena et al. 2002; Roy et al. 2000; Suda et al. 2004), no high-throughput assay has been 
developed yet.  
2.3. N-Glycosylation control and modulation  
N-glycosylation can be controlled and tuned by media and feed, culture process and genetic 
engineering approaches. In the following section, different strategies to influence protein N-
glycosylation will be reviewed.   
2.3.1. Media, feed and culture process 
Manipulation of process parameters and optimization of media and feed are the traditional 
approaches to improve cell growth and product titer. These approaches have also been demonstrated 
to be efficient in controlling protein N-glycosylation (Hossler et al. 2009). Classical media 
components in animal cell culture, for example glucose, galactose, glutamine, NH4
+
, and other 
amino acids and typical feed additives such as manganese, sodium butyrate, and nucleotide and 
nucleotide sugar precursors have been shown to have a crucial influence on N-glycosylation. 
Additionally, impact of process parameters including dissolved oxygen, pCO2, pH, temperature, 
agitation rate, and culture duration on N-glycosylation has also been well studied in animal cell 
culture. In table 2.2, we summarized the updated main findings reported in this field.  
 
Table 2.2. Effect of media, feed and culture process on therapeutic protein N-glycosylation.  
IFN-β: Interferon beta; IFN-γ: Interferon gamma; EPO: Erythropoietin; CTLA4Ig: Fusion protein of 
cytotoxic T-lymphocyte-associated protein 4 and antibodies; TIMP-1: Tissue inhibitor of metalloproteinase 1; 
TNFR-IgG: Fusion protein of tumor necrosis factor receptor and IgG; tPA: Tissue plasminogen activator. 
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Variables Effect on protein N-glycosylation Reference 
Glucose  Glucose starvation decreased site occupancy, 
galactosylation and sialylation of mAb. 
 Glucose limitation increased high mannose and 
decreased sialylation of IFN-γ. 
 Glucose limitation decreased site occupancy of IFN-γ 
by limiting UTP and consequently UDP-GlcNAc 
synthesis.  
 Glucose addition increased galactosylation of mAb. 
 High specific glucose consumption rate improved the 
maturation of glycans of mAb.  
 Glucose starvation at stationary phase of fed-batch 
culture reduced specific productivity of mAb (qp) and 
thus improved the maturation of glycans of mAb. 
(Liu et al. 2014) 
(Chee Furng Wong et al. 2005) 
(Nyberg et al. 1999) 
(Nahrgang et al. 2002) 
(Fan et al. 2014) 
(Chapter 6) 
 
Galactose  Galactose feeding increased fully galactosylated N-
glycans. 
 Galactose feeding increased galactosylation of a 
CTLA4Ig fusion protein. 
 Galactose addition increased galactosylation of mAb. 
(Andersen 2004) 
(Schilling et al. 2008)  
(Chapter 4) 
Glutamine  Glutamine limitation decreased site occupancy of IFN-γ 
by limiting UDP-GlcNAc synthesis. 
 Glutamine limitation increased Man5 glycan in mAb by 
limiting UDP-GlcNAc synthesis. 
 Glutamine addition lead to high ammonium 
accumulation, and thus decreased galactosylation and 
sialylation of a recombinant TNFR-IgG fusion protein. 
(Nyberg et al. 1999) 
(Fan et al. 2014) 
(Gawlitzek et al. 2000) 
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Amino acids  Supplementing amino acids (cysteine, isoleucine, 
leucine, tryptophan, valine, asparagine, aspartate, and 
glutamate) that have been depleted in the cell culture 
increased sialylation of EPO. 
 High specific amino acid consumption rate increased 
NH4
+
 concentration in cell culture and thus increased 
Man5 glycan of mAb. 
(Crowell et al. 2007) 
(Fan et al. 2014) 
NH4
+
  High NH4+ concentration decreased galactosylation and 
sialylation of a recombinant TNFR-IgG fusion protein. 
 High NH4+ concentration correlated with low GlcNAc 
occupancy and high Man5 glycan of mAb. 
(Gawlitzek et al. 2000) 
(Fan et al. 2014) 
Mn2
+
  Addition of Mn2
+
 increased site occupancy of N-
glycosylation, galactosylation of EPO. 
(Crowell et al. 2007) 
Nucleotide 
and  
nucleotide 
sugar 
precursors 
 N-acetylmannosamine (ManNAc) addition increased 
sialylation of IFN-γ. 
 Glucosamine addition decreased EPO sialylation. 
 Glucosamine and uridine supplementation increased N-
glycan antenarity, but decreased sialylation of TIMP-1 
produced in CHO.  
 Feeding galactose + uridine + Mn2
+
 increased 
galactosylation of mAb. 
 Feeding galactose ± uridine, glucosamine ± uridine and 
ManNAc ± cytidine increased sialylation of IFN-γ. 
(Gu and Wang 1998) 
(Yang and Butler 2002) 
(Baker et al. 2001) 
(Gramer et al. 2011) 
(Wong et al. 2010b) 
Sodium 
butyrate 
 Sodium butyrate addition increased sialylation of IFN-γ. 
 Sodium butyrate addition decreased mAb 
galactosylation. 
 Sodium butyrate addition increased tPA site occupancy 
of Asn-184. 
 Sodium butyrate addition decreased N-
(Lamotte et al. 1999) 
(Hong et al. 2014) 
(Andersen et al. 2000) 
(Borys et al. 2010) 
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glycolylneuraminic acid (NGNA) content of a 
recombinant fusion protein. 
Glycerol  Glycerol addition increased sialylation of IFN-β (Rodriguez et al. 2005) 
Monensin   Addition of monesin increased high mannose glycan of 
mAb. 
(Rothman et al. 1989) 
Lipids  Lipids increased site occupancy of IFN-γ. 
 Lipoprotein addtion increased the the proportion of 
fully-glycosylated IFN-γ. 
(Castro et al. 1995) 
(Jenkins et al. 1994) 
DMSO  DMSO addition decreased sialylation of IFN-β. (Rodriguez et al. 2005) 
pH  Different culture pH (6.9, 7.2 and 7.4) setpoints affected 
galactosylation and sialylation of mAb. 
 Lowing culture pH increased sialylation of EPO. 
 pH variations (< 6.9 and > 8.2) decreased overall 
glycosylation of a mouse placental lactogen. 
 Using sodium hydroxide instead of sodium carbonate as 
the base to regulate culture pH, decrease NGNA content 
of a recombinant fusion protein. 
(Muthing et al. 2003) 
(Yoon et al. 2005) 
(Borys et al. 1993) 
(Borys et al. 2010) 
 
pCO2  Elevated pCO2 decreased polysialylation. 
 Elevated pCO2 deceased NGNA content of tPA. 
(Zanghi et al. 1998) 
(Kimura and Miller 1997) 
Temperature  Temperature shift from 37°C to 33 or 30°C decreased 
sialylation of an EPO-Fc fusion protein. 
 Sialylation profiles of EPO are comparable among 
culture temperature at 37, 33 or 30°C. 
 Late temperature shift near the stationary phase 
compared to early temperture shift at exponential phase 
decreased NGNA content of a recombinant fusion 
protein. 
(Trummer et al. 2006) 
(Yoon et al. 2003) 
(Borys et al. 2010) 
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Dissolved 
oxygen 
 Decreased level of DO reduced galactosylation of mAb. 
 High DO increased NANA content of a recombinant 
follicle stimulating hormone. 
  Low DO caused almost no change in the glycosylation 
of tPA. 
 The effect of DO on glycosylation seems to be cell 
specific and/or protein specific. 
(Kunkel et al. 1998) 
(Chotigeat et al. 1994) 
(Lin et al. 1993) 
(Hossler 2012) 
Agitation rate  High agitation rate that caused high shear stress 
deceased N-glycan site occupancy of mAb. 
(Senger and Karim 2003) 
Culture 
duration 
 Increased culture duration increased high mannose 
structure of mAb 
 Increaed culture duration increased Man5 glycan of 
mAb 
 Increased culture duration along with reduced viability, 
decreased sialylation of IFN-γ. 
 Increased culture duration decreased the GlcNAc 
occupancy and galactosylation of mAb. 
(Robinson et al. 1994) 
(Pacis et al. 2011) 
(Chee Furng Wong et al. 2005) 
(Chapter 6) 
2.3.2. Genetic engineering of glycosylation-related enzymes 
The abilities of processing protein glycosylation inherent in various cell lines are largely related to 
the activities of a repertoire of glycosylation-related enzymes. These enzymes, such as 
glycotransferases, glycosidases, and nucleotide sugar transporters are typically located in ER or 
Golgi and involve in biosynthesis and degradation of glycans. Many successful attempts at 
modulating protein glycosylation toward desired patterns have been shown by CHO cell line 
engineering of these enzymes individually or in combinations. These attempts have included 
strategies such as knock-in of new genes, and overexpression and knock-down/out existed genes in 
the cells.  
As mentioned in earlier section, high NANA content is beneficial for increasing the serum half-life 
of recombinant therapeutic proteins. Therefore, many effects have been put into the area of 
maximizing NANA level for recombinant therapeutic proteins. A research group that over-
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expressed α-2, 3-sialyltransferase (α-2, 3-SiaT) in CHO cells, significantly increased NANA 
content and decreased the microheterogeneity in the produced a fusion protein of tumor necrosis 
factor receptor and IgG (TNFR-IgG) and tissue plasminogen activator (tPA) (Weikert et al. 1999). 
Another research group targeted this issue from an opposite direction by reducing the removal of 
NANA residues from glycan. They knock-down sialidase expression using antisense RNA, which 
increased NANA content of the produced Dnase (Ferrari et al. 1998).  Additonally, increasing 
sialylation has also done by using a strategy of improving the availability of CMP-sialic acid as 
well. This has been achieved through knock-down the expression of CMP- sialic acid hydroxylase 
to increase the intracellular level of CMP- sialic acid (Chenu et al. 2003), as well as overexpression 
of CMP-sialic acid transporter (Wong et al. 2006) to increase CMP-sialic acid abundance in Golgi 
apparatus. 
In order to improve ADCC activity of IgG, many attempts at, for example, adding bisecting 
GlcNAc structure to glycan and removing fucose residue from glycan were performed. A number of 
studies showed that knock-in N-acetylglucosaminyltransferase III (GnTIII) in CHO cells can 
introduce a bisecting GlcNAc structure into the glycan of produced IgG (Davies et al. 2001; Umana 
et al. 1999). Additionally, many strategies have been proposed to increasing the removal of fucose 
residue in the glycan. Some of the most pronounced ones are knock-down/out fucosyltransferase 
VIII (FucTVIII) and/or GDP-mannose 4, 6-dehydratase (GMD) in order to partially or completely 
block GDP-Fucose biosynthesis and eventually reduce the level of fucosylation (Imai-Nishiya et al. 
2007; Kanda et al. 2007; Mori et al. 2004; Yamane-Ohnuki et al. 2004). Alternative approach of 
reducing fucosylation was also reported by a group of researcher recently. They reduced the 
availability of GDP-Fucose by knock-in a bacteria enzyme GDP-6-deoxy-D-lyxo-4-hexulose 
reductase (RMD) found in Pseudomonas aeruginosa into a CHO cell line producing IgG (von 
Horsten et al. 2010). This enzyme can redirect a precursor in the GDP-Fucose biosynthesis pathway 
towards generating a new compound rather than GDP-Fucose.  
Recent CHO genome sequencing presents us great potential and more targets for implementing 
genetic engineering of glycosylation (Xu et al. 2011). In comparison with human genome, a number 
of non-expressed genes in CHO-K1 cell line were founded, including GnTIII, α (1,2), α (1,3) and α 
(1,4)-linked fucosyltransferases and α-2,6-sialyltransferase. Therefore, knock-in of these genes may 
establish CHO cell lines with gain-of-function phenotypes.  On the other hand, there are also 
glycosylation genes found in CHO genome but not to be expressed in humans, for example cytidine 
monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) which can hydroxylate NANA to 
NGNA and α(1,3) galactosyltransferase which can produce galactose-α-1,3-galactose glycan 
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structure. The expression of these genes has to be well-controlled because they have the potential to 
produce foreign glycan structure, which may trigger immunogenic responses in human. More 
successful cases regarding genetic engineering of glycosylation can be reviewed in Table 2.3. 
Table 2.3. A list of reported genetic engineering of glycosylation in CHO cells. Abbreviations: GnT: N-
acetylglucosaminyltransferase. FucT: fucosyltransferase. SiaT: sialyltransferase. GalT: galactosyltransferase. 
GMD: GDP-mannose 4,6-dehydratase. RMD: GDP-6-deoxy-D-lyxo-4-hexulose reductase. 
Target enzymes Method Effect Reference 
α-1,6-FucT 
(FucTVIII) 
Knock-out 
Complete removal of fucose in 
glycans of mAb 
(Yamane-Ohnuki 
et al. 2004) 
α-1,6-FucT 
(FucTVIII) 
Knock-down Increase afucosylation of mAb (Mori et al. 2004) 
α-2,3-SiaT Overexpression 
Increase sialylation of a TNFR-IgG 
fusion protein 
(Weikert et al. 
1999) 
α-2,6-SiaT Knock-in Increase sialylation of EPO (Zhang et al. 1998) 
α-2,6-SiaT Knock-in Increase sialylation of mAb (Jassal et al. 2001) 
β-1,4-GalT Overexpression 
Increase galactosylation of a TNFR-
IgG fusion protein 
(Weikert et al. 
1999) 
Sialidase Knock-down Increase sialylation of DNAse 
(Ferrari et al. 
1998) 
CMP-sialic acid  
transporter 
Overexpression Increase sialylation of IFN-γ (Wong et al. 2006) 
CMP-N-
acetylneuraminic 
acid hydroxylase 
Knock-down 
Reduce NGNA content of the cells' 
own glycoconjugates 
(Chenu et al. 2003) 
UDP-GlcNAc 
transporter 
Overexpression 
Partially restored galactosylation of 
glycoprotein in a mutant CHO cell 
line defective in UDP-Gal transporter 
(Maszczak-
Seneczko et al. 
2011) 
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UDP-GlcNAc 
transporter 
Overexpression 
Cannot increase GlcNAc and Gal 
occupancy of mAb 
(Chapter 7) 
GnTI Knock-out 
Produce mAb with 100% high 
mannose glycans 
(Sealover et al. 
2013) 
GnTI Overexpression Increase GlcNAc occupancy of mAb (Chapter 7) 
GMD Knock-out 
Complete removal of fucose in 
glycans of mAb 
(Kanda et al. 2007) 
GMD and α-1,6-
FucT (FucTVIII) 
Knock-down Generating fully non-fucosylated mAb 
(Imai-Nishiya et 
al. 2007) 
GnT III Knock-in Addition of bisecting GlcNAc of mAb 
(Davies et al. 
2001; Umana et al. 
1999) 
GnTV Knock-out 
Eliminate all tetra-antennary structures 
by complete removal of GlcNAcβ 
(1,6)Manα(1,6)-branched N-glycans 
(North et al. 2010) 
α-1,3-FucT 
(FucTVI) 
Knock-in 
Addition of single or multiple 
fucosylation structures including 
Lewis
x
, sialyl Lewis
x
 structures and 
their combinations. 
(North et al. 2010) 
α-1,3-FucT 
(FucTIV and 
FucTIX) 
Knock-in 
Addition of extremely high amount of 
single or multiple Lewis
x
 fucosylation 
structures. 
(North et al. 2010) 
α-1,3-FucT 
(FucTIX) 
Knock-in 
Addition of single or multiple Lewis
x
 
fucosylation structures. 
(North et al. 2010) 
Arthrobacter 
ureafaciens 
sialidase A 
catalytic domain 
Knock-in Decreased sialylation of mAb (Naso et al. 2010) 
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RMD Knock-in Reducing fucosylation of mAb 
(von Horsten et al. 
2010) 
2.4. Executive summary 
 Understanding and in-depth knowledge on the function of N-glycosylation in therapeutic 
protein is important in development of biopharmaceuticals as it can provide the target 
glycopatterns for glycosylation modulation and optimization. 
 The future trend of development in analytical techniques accessing N-glycosylation is towards 
faster, simpler, higher resolution and throughput methods that can analyze factors that involves 
in glycosylation process from multiple aspects (e.g. structure of glycans, abundance of 
precursors for glycosylation, activity of glyco-related enzymes) during different stages of 
process development.  
 Controlling and modulating N-glycosylation for better therapeutic proteins can be achieved 
through process and media optimization, genetic engineering of cell lines and the combinations 
of these strategies.     
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Chapter 3 Effect of glucose and amino acid metabolism on N-
glycosylation 
In this chapter, we will present our work on manipulating N-glycosylation by changing the amino 
acid and glucose consumption rates in the CHO fed-batch cultures. This work has been published in 
Biotechnology and Bioengineering, 2014. We demonstrated that during process and media 
optimization, the balance of glucose and amino acid concentration in the culture was essential for 
cell growth, IgG titer and N-glycosylation. It was possible to direct glycosylation quality of 
monoclonal antibody by well controlling the glucose and amino acid metabolism.  
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Abstract 
Therapeutic monoclonal antibodies (mAbs) are mainly produced by heterogonous expression in 
Chinese hamster ovary (CHO) cells. The glycosylation profile of the mAbs has major impact on the 
efficacy and safety of the drug and is therefore an important parameter to control during production. 
In this study, the effect on IgG N-glycosylation from feeding CHO cells with eight glycosylation 
precursors during cultivation was investigated. The study was conducted in fed-batch mode in 
bioreactors with biological replicates to obtain highly controlled and comparable conditions. We 
assessed charge heterogeneity and glycosylation patterns of IgG. None of the eight feed additives 
caused statistically significant changes to cell growth or IgG productivity, compared to controls. 
However, the addition of 20 mM galactose did result in a reproducible increase of galactosylated 
IgG from 14 % to 25 %. On the other hand, addition of 20 mM N-acetyl-D-glucosamine (GlcNAc) 
reduced relative abundance of galactosylated IgG by 4%. Additionally, supplementation with 
10mM mannose slightly reduced GlcNAc occupancy of IgG. Overall, comparing the effects of IgG 
glycosylation, by supplementing the cell culture medium with glycosylation precursors during 
cultivation, revealed an application of these glycosylation precursors for modulating N-
glycosylation of IgG.  
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4.1. Introduction 
The production of monoclonal antibodies (mAbs) of the IgG isotype is a large and rapidly 
expanding area of biotechnology. In 2009, the market for mAbs constituted 38% of a 99 billion 
dollar market for biopharmaceuticals (Walsh 2010), and expanded to 45% in 2013. In nearly all 
cases, the mAb is produced in Chinese hamster ovary (CHO) cells (Walsh 2014). There is thus great 
commercial interest in production of IgGs in CHP cells, but the production requires considerable 
know-how to achieve sufficient quality of the produced IgG. IgG glycans play a critical role in a 
number of IgG effector functions including antibody dependent cellular cytotoxicity (ADCC) (Raju 
2008). The length and structure of the glycan furthermore affects stability and clearance (Jones et al. 
2007; Sola and Griebenow 2009; Stockert 1995). Important N-glycan features, influencing IgG 
properties include alpha-1,6-fucosylation of the glycan core (Shields et al. 2002), the 
presence/absence of a bisecting N-acetylglucosamine (Umana et al. 1999), and the termination of 
N-glycan antennae with a sialic acid residue  (Scallon et al. 2007). For IgG glycans, the largest 
variation of N-glycans is the number of D-galactose residues (Huhn et al. 2009). 
The glycosylation profiles of therapeutic proteins, including IgGs, can be highly affected by the cell 
line, medium composition and cultivation process conditions (Costa et al. 2013; Hossler 2012). 
Since glycosylation is an important parameter for IgG function, strategies to modify glycosylation 
profiles of human IgG or to select the most efficient glycoforms have been explored. While genetic 
engineering has been employed in many cases, it is often simpler to implement changes to the cell 
culture medium (For a review, see (Andersen et al. 2009)).  
Within this study, we have focused on groups of known and potential precursors for the sugar 
residues constituting the N-glycan chains. The effect on the N-glycosylation of multiple model 
proteins by addition of precursors has been performed in human, mouse and CHO cells, e.g. for D-
galactose (Andersen 2004; Clark et al. 2005; Hills et al. 2001; Schilling et al. 2008; Tachibana et al. 
1994; Wong et al. 2010) and D-mannose (Tachibana et al. 1994). Similar studies on varied cells and 
proteins have also been made on N-acetylated sugars, namely N-acetyl-D-glucosamine (GlcNAc) 
(Tachibana et al. 1997), and N-acetyl-D-mannosamine (ManNAc) (Baker et al. 2001; Gu and Wang 
1998; Hills et al. 2001; Pels Rijcken et al. 1995; Zanghi et al. 1998). Furthermore, the effect of 
adding nucleotide precursors for nucleotide-sugar donors, involved in N-glycan biosynthesis, has 
been examined for uridine and cytidine (Wong et al. 2010; Zanghi et al. 1998). While all of these 
compounds are reported to affect N-glycosylation in one or more studies, several of these studies 
report divergent or even contradictory effects on protein N-glycosylation. This variation may be due 
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to the diversity of the applied cell lines, model proteins and cultivation methods in particular, most 
of these studies are conducted in non-controlled shake flask cultures. 
In this study, we have investigated, under production-like conditions (fed-batch controlled 
bioreactors), whether supplementing the cell culture medium with a wide range of N-glycan 
precursors affects the N-glycosylation of IgG produced in CHO cells. This setup allows a close 
mimicry of the commercially important process of production of recombinant pharmaceutical 
antibodies. The investigated compounds include D-(+)-Mannose, D-galactose, L-fucose, GlcNAc, 
ManNAc, N-Acetylneuraminic acid (NeuNAc), uridine, and cytidine. To our knowledge none of 
these compounds have been investigated in an IgG-producing CHO cell line before, and the results 
for especially D-galactose and ManNAc have been highly divergent in the conditions studied 
(Andersen et al. 2009). Analysis of the effect of NeuNAc has not been performed anywhere, to our 
knowledge. We have performed detailed N-glycosylation profiles to address this.  
4.2. Materials and Methods 
4.2.1. Cell culture 
A CHO DG44-derived suspension cell line secreting recombinant IgG antibody (kindly provided by 
Symphogen A/S, Denmark) were routinely cultured in shake flasks with serum- and glutamine-free 
PowerCHO-2 CD (Lonza) medium supplemented with 5 mM L-Glutamine (Lonza), 1/100 Mem-
NEAA (Lonza) and 1/40 Anti-clumping agent (Gibco). The cells were maintained in a humidified 
incubator at 37˚C, 5 % CO2 and 100 rpm. Inoculum for each round of 4 parallel fed-batch 
bioreactors was prepared from one ampule of 10
7
 cells.. 
4.2.2. Fed-batch cultures 
Fed-batch cultures of cells were performed using four paralleled SR0700 bioreactors with a 
working volume of 200-1000 mL. Cultivations were controlled by a PH4PO4 sensor module, a 
MX4/4 gassing system, two MP8 multipump modules, and a TC4SC4 temperature and agitation 
control unit (Dasgip, Germany). Temperature was maintained at 36.8˚C applying a CWD4 cooling 
water distribution unit (Dasgip, Germany) with a WK500 chiller (LAUDA, Germany). pH was 
maintained at 6.95 by the sparging of CO2 or the addition of 0.5 M Na2CO3. The dissolved oxygen 
concentration was maintained at 30 %. Cells were agitated at 80 rpm using a marine impeller. 325 
mL medium in each bioreactor were inoculated with a post-inoculum density of 4x10
6
 cells/ml to 
ensure a high culture density and relatively fresh medium at the time of the feeding of additives. At 
the time of inoculation, feed was cell culture medium with 8 mM L-glutamine and no anti-clumping 
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agent. The temperature was shifted to 32˚C after 24 hours. After 48 hours, the bioreactors were 
spiked with the repective additives to achieve final media concentration of 20 mM N-acetyl-D-
glucosamine (GlcNAc, A3286, Sigma-Aldrich), 20 mM N-acetyl-D-mannosamine (ManNAc, 
A8176, Sigma-Aldrich, 10 mM L-fucose (F2252, Sigma-Aldrich), 0.5 mM uridine (U3003, Sigma-
Aldrich), 0.5 mM cytidine (C4654, Sigma-Aldrich), 10 mM D-(+)-mannose (M6020, Sigma-
Aldrich), 0.5 mM N-acetylneuraminic acid (NeuNAc, A2388, Sigma-Aldrich) or 20 mM D-
galactose. The feed was changed to feed with matching concentration of the additive. Glucose was 
spiked into the bioreactor to obtain 12 mM every time the level decreased below 8 mM. Feed was 
added to cell culture every 24 hours from 0 h to 216 h with a volume of 57.7, 51.4, 43.1 34.5, 32, 
29.9, 27.8, 26.9, 18.8 and 18.8 ml, respectively. The cultures were discontinued after 336 hours. 
Additives were dissolved in feed medium and sterile filtered before addition to feed bottles or 
spiked into the bioreactor. Controls were run in triplicate and additives in duplicate to allow for 
correct evaluation of biological variance.  
4.2.3. Cell, metabolite and product analysis 
Daily samples of 2 mL cell suspension were collected and cell viability was measured using a NC-
100 nucleocounter (Chemometec, Denmark). Cell–free samples for measurement of metabolite and 
product concentration were obtained by centrifugation at 20.000 g for 5 min. At the final day, day 
14, samples of 50 mL were harvested and cleared for cells by centrifugation at 400 g for 5 min at 
4˚C. Samples were stored at -20˚C until analysis. Glucose, lactate, glutamine and glutamate 
concentrations in cell-free supernatant samples were measured using Yellow Spring Instrument 
(YSI) analyzers (model 2300 and 2700). Values were normalized against standards of known 
concentrations. Recombinant IgG antibody secreted in cell-free supernatant samples were 
quantified by direct measurement of the binding of IgG to protein A-coated sensors (Fortebio, 
USA). Samples were calibrated against a standard curve created from measurement of known 
concentrations of IgG. 
4.2.4. Purification of IgG 
Clarified supernatants were filtered through a 0.22 µm low protein-binding filter (Millipore) to 
obtain cell free samples. Purification of IgG was conducted on self-packed MabSelect SuRe Protein 
A column (GE Healthcare) with 200 µl of protein A resin slurry. The IgG were purified according 
to manufacturer’s recommendations using phosphate-buffered saline (PBS) as wash buffer and 100 
mM citrate with pH 3.5 as elution buffer. The eluted IgG were directly applied onto a NAP-5 
column (GE Healthcare) and eluted with a buffer containing 10 mM citrate and 150 mM NaCl with 
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pH 6.0. The concentration of the purified IgG were determined by NanoDrop ND-1000 (Thermo 
Scientific) and stored at -20˚C. 
4.2.5. Cation-exchange chromatography of IgG 
10 µg of purified IgG per sample were injected in to a Dionex summit system equipped with a p680 
pump, UVD170U detector at 280 nm, ASI100 automated sample injector with 1000 µl loop and 
ProPac WCX-10 column 250x4 mm. The column was equilibrated with 95% Buffer A (25 mM 
sodium acetate pH 5) and 5% Buffer B (25 mM sodium acetate, 0.5M sodium chloride pH 5), and 
protein was separated at a flow rate of 1 ml/min with a linear gradient of Buffer B from 5 to 100% 
over 38 min. The chromatograms were quantified by integration of the heterogeneous peak, which 
is divided into acidic isoforms, main peak and basic isoforms. The cut-offs at the main peak is set at 
retention time of the highest peak -0.25 min. and +0.14 min.   
4.2.6. Intact mass analysis of IgG 
Intact mass analysis was performed the same as described by Fan et al. (2014). The mass of the IgG, 
without glycosylation, is 145499.8 Da. The assigned peaks were quantitated in the Dionex-
Chromeleon Chromatography Data System. 
4.2.7. Instant-AB labeled glycoprofiling 
50 µg of purified IgG per sample have been processed according to instruction of instant AB
TM
 
GlykoPrep
®
 kit (Prozyme). Labeled glycans were eluted with Milli-Q water, diluted 1:1 with 100 % 
acetonitrile and applied to HPLC analysis as reported previously (Fan et al. 2014).  
4.2.8. Statistical analysis of glycoform distributions 
The integral of cell density (IVC) at harvest, the average cell specific productivity (PCD) from day 
3 to day 6, and the distributions of charge variants and glycoforms were evaluated statistically in 
comparison of experiments to control. Evaluation of statistical significance (p < 0.05) was 
calculated in a one-way ANOVA employing Dunnett 's post hoc pairwise comparison test using 
GraphPad Prism 5. 
4.3. Results  
To compare the effect of adding glycosylation precursors to the culture medium during cultivations, 
fed-batch cultivations of an IgG-producing CHO cell line were conducted in controlled bioreactors 
in order to investigate the effect on cell growth, product formation, charge heterogeneity, and 
glycosylation profiles of the produced IgG.  
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Figure 1. Fed-batch culture performance of three independent controls. (A) viable cell density, (B) viability, 
(C) integral of viable cell density, (D) IgG titer, (E) glucose/lactate concentration and (F) 
glutamine/glutamate concentration. 
4.3.1. Fed-batch culture 
Fed-batch cultures were performed under highly controlled conditions to minimize the effect of 
cultivation parameters on the glycosylation of IgG. Cell growth was minimized 24 hours after 
inoculation by a temperature shift; thus also increasing IgG productivity. To analyze the effect of 
adding glycosylation precursors to the cell culture medium, control cultivations were conducted and 
compared to cultures supplemented with one of the following eight compounds: D-(+)-Mannose, L-
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Fucose, D-galactose, GlcNAc, ManNAc, NeuNAc, uridine, and cytidine.  Cell growth and viability 
were highly reproducible in our controls (Figure 1A-C). IgG titer showed minor variations with a 
maximum difference of app. 13% on day 14 (Figure 1 D). The lactate concentration of the three 
different controls was slightly variable with the maximum values at day 2. Glucose concentration 
also varied slightly among the controls, whereas concentrations of glutamine and glutamate were 
highly comparable. Overall, our setup gives reproducible results on cell growth, key metabolites, 
and protein production. 
 
Figure 2. Comparing glycosylation precursor supplemented cultivations to controls. (A) Integral of viable 
cells, (B) Cell specific productivity. Statistically significant differences are indicated as: * for p<0.05, ** for 
p<0.01 and *** for p<0.001. 
The profiles of cell growth and IgG titer in cultivations supplemented with glycosylation precursors 
are given in Figure S1 and S2. Data related to the cultures with and without addition of 
glycosylation precursors are summarized in Table SI. No statistically significant differences were 
observed between controls and the cultures with additives, although addition of D-mannose seems 
to slightly increase the IVC (Figure 2A). Cell specific productivities (qp) of the cultures with 
additives showed a mild reduction compared to the controls (Figure 2B), except L-fucose and 
NeuNAc which gives values close to the controls. However, none of these reductions were 
statistically significant, indicating that the concentrations of the additives used in our setup had no 
apparent negative effect on IgG specific production rates. 
In summary, all of the additives have no statistically significant adverse effects on cell growth and 
IgG production, making any differences in glycoform frequencies comparable between experiments. 
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4.3.2. Effect of additives on charge heterogeneity and glycosylation of antibody 
To analyze the effect of additives on the glycosylation of the IgG produced by the cells, IgG were 
purified from the supernatant on the last day of cultivation (day 14). The intact mass analysis was 
performed to provide quantification of the N-glycans on the IgG molecules. 
 
Figure 3. Distribution of charge isoforms of IgG produced from controls and the cultures with feed additives. 
Statistical significance: * for p<0.05, ** for p<0.01 and *** for p<0.001. 
The purified antibodies were analyzed for IgG charge heterogeneity (Figure 3). We see no 
significant changes in IgG charge between the controls and different additives occur. This suggests 
that post-translational modifications, for example C-terminal lysine processing, deamidation and 
oxidation, which can affect the net surface charges and conformational structure of IgG, are 
relatively constant among the different groups. 
Furthermore, we examined glycan combinations detected on the purified IgG (Figure 4). In the 
groups with galactose added, we saw highly significant (p<0.001) decrease of less processed glycan 
combinations (A1G0F/G0 and G0F/G0F) and increase (p<0.001) of glycan combinations with more 
galactose residues (G0F/G1F, G1/F/G1F or G0F/G2F and G1F/G2F). In contrast to galactose 
addition, GlcNAc induces an opposite effect, namely a small increase in A1G0F/G0 and G0F/G0F 
glycans at the expense of the higher glycosylated forms. Notably, and contrary to several of the 
previous reported studies, the other additives tested did not cause significant changes to the glycan 
combinations.  
To achieve more detailed information of N-glycan distribution, glycoprofiling using instant-AB 
labeling was conducted to complement the intact mass analysis (Figure 5). In brief, we identified no 
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statistical significant changes in GlcNAc occupancy between the controls and the groups with 
additives, except for mannose addition experiments, which exhibit a lower GlcNAc occupancy 
(Figure 5A). This is likely due to elevated levels of high mannose forms (Figure S3). Comparison 
of the relative abundance of galactosylation confirmed a highly significant (p<0.001) increase in the 
amount of galactose residues attached to the glycans resulting from D-galactose addition (Figure 
5B). This was evident in a lower level of G0F glycosylation, a large increase in G1(1,6)F and to a 
lesser extent G1(1,3)F and G2F glycosylation (Figure S3). Additionally, GlcNAc addition was 
shown to inhibit galactosylation. Interesting, a slight increase in fucosylation (p<0.05) was observed 
from ManNAc supplementation. None of the other additives had any significant effects. 
 
 
Figure 4. Intact mass analysis of IgG produced from controls and the cultures with feed additives. Statistical 
significance: * for p<0.05, ** for p<0.01 and *** for p<0.001. 
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Figure 5. Glycoprofling of IgG produced from controls and the cultures with feed additives.  (A) Relative 
abundance of GlcNAc occupancy, (B) Relative abundance of galactosylation, (C) Relative abundance of 
fucosylatuion. The GlcNAc occupancy and galactoslyation was calculated as described in  (Fan et al. 2014) 
Statistical significance: * for p<0.05, ** for p<0.01 and *** for p<0.001. 
4.4. Discussion 
The availability of intracellular nucleotide sugars (NSs) is key to controlling N-glycosylation (Fan 
et al. 2014). The feed additives were expected to increase intracellular NS pool by increasing their 
biosynthesis. In Figure 6, all feed additives used in this study were mapped into the biosynthesis 
pathway of NSs in order to help understand their effects on cell metabolism.  
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Figure 6. Integrated map of nucleotide sugar synthesis pathway and feed additives. Red rectangle: 
nucleotide sugars; Blue circle: feed additives studied. Galactose (Gal); Glucose (Glc); Mannose (Man); 
Fucose (Fuc); N-acetyl-D-glucosamine (GlcNAc); N-acetyl-D-mannosamine (ManNAc); N-
Acetylneuraminic acid (NeuNAc) 
It has previously been demonstrated that supplementing galactose can increase galactosylation of 
recombinant proteins (Andersen 2004; Schilling et al. 2008). This was in line with our finding of 
increased galactosylation of IgG without affecting cell growth and qp. It has also been reported that 
addition of 10 mM galactose increases the UDP-Gal pool nearly five-fold in GS-NS0-cells (Hills et 
al. 2001). This may be attributed to the relatively short biosynthesis pathway from galactose to 
UDP-Gal (Figure 6). Considering these results, we propose that the biosynthesis of UDP-Gal is a 
limiting factor for galactosylation of the IgG in our cell line. Addition of galactose to the culture 
media may elevate the intracellular concentration of UDP-Gal and subsequently increase the 
presence of terminal galactose residues in the glycans. 
Unexpectedly, addition of 20 mM GlcNAc decreased galactosylation. This may be explained by the 
fact that UDP-GlcNAc has to be transported into Golgi apparatus to partake in glycosylation 
processes. Supplementing GlcNAc may enhance the biosynthesis of UDP-GlcNAc and increase its 
intracellular concentration. Since no increase in GlcNAc occupancy was observed, we suggest that 
the cellular level of UDP-GlcNAc was sufficient for delivery of GlcNAc residues for N-
glycosylation. On the other hand, we have shown that the UDP-Gal pool is a limiting factor for 
galactosylation in this cell line. It has also been reported that UDP-GlcNAc transporter can partially 
restore galactosylation in a CHO cell line, which is defective in UDP-Gal transport (Maszczak-
Seneczko et al. 2011). This indicates that UDP-Gal is transported into the Golgi apparatus via, 
UDP-Gal transporters but also UDP-GlcNAc transporters. Increases in intracellular UDP-GlcNAc 
concentrations, caused by GlcNAc feeding, may compete with UDP-Gal for Golgi 
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loading/uptake/import, reduced availability of UDP-Gal inside Golgi apparatus and consequently 
decrease galactosylation. 
Supplementation with 10mM mannose slightly increased high mannose glycoforms levels and 
consequently decreased GlcNAc occupancy of the produced IgG. This indicates that an excess of 
intracellular mannose may increase the intracellular GDP-Man pool. 
No increase in fucosylation of the IgG was detected in this study, even though addition of fucose 
was reported previously to enhance GDP-Fuc biosynthesis and subsequent incorporation into 
glycans (Pels Rijcken et al. 1995). This implies that the abundance of intracellular GDP-Fuc is not a 
limiting factor of fucosylation in our process. Therefore, the bottleneck of fucosylation in this case 
may be the activity of the fucosyltransferase and not metabolic effect of the additives. For these 
reasons, we suggest that the minor increase in fucosylation, when adding ManNAc to the cell 
culture, was unrelated to NS metabolism. 
As shown in Figure 6, ManNAc and NeuNAc addition may increase the flux towards CMP-
NeuNAc and enhance sialylation of IgGs in our cell line. This effect has been confirmed for the 
production of interferon gamma (IFN-γ) (Gu and Wang 1998; Wong et al. 2010). However, 
different results were reported elsewhere (Baker et al. 2001; Hills et al. 2001), where feeding with 
20 mM ManNAc had no effect on sialylation of recombinant proteins (IgG and TIMP-1), even 
though an increase in intracellular concentration of CMP-NeuNAc was confirmed. In our case, the 
sialylation of IgG is extremely low in the controls (<0.2%, Figure S3), and no change was observed 
when feeding ManNAc or NeuNac. This is possibly due to the main limitation of IgG-sialylation 
being steric hindrance of the sialyl transferase. Additionally, it has been demonstrated that increased 
intracellular level of CMP-NeuNAc can lead to strong feed-back inhibition of UDP-GlcNAc 2-
epimerase activity. This in turn prevented ManNAc biosynthesis from UDP-GlcNAc in rat 
hepatocytes (Pels Rijcken et al. 1995). Therefore when supplementing ManNAc and NeuNAc to 
cell cultures, we would further expect a slightly increased accumulation of UDP-GlcNAc. This 
should lead to a decrease in galactosylation. This effect has actually been observed in Figure 5B, 
although the decrease is minor and not statistically significant. 
Uridine or cytidine addition did not change the glycosylation patterns in our study, which indicates 
that these two additives are not limiting factors for the NSs biosynthesis and glycosylation in our 
cell line. However, many studies show that combining uridine or cytidine with other NS precursors 
(for example uridine + galactose, uridine + GlcNAc, and cytidine + ManNAc) can lead to a 
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synergistic effect on glycosylation (Baker et al. 2001; Grainger and James 2013; Gramer et al. 2011; 
Wong et al. 2010). 
In conclusion, supplementing cell cultures with glycosylation precursors can be a fast and effective 
way of modulating some features of N-glycosylation of recombinant proteins. For example, 
addition of galactose consistently increased galactosylation of IgG in this process. Additionally, 
most of other additives tested didn’t show a significant effect on glycosylation patterns. However, 
several metabolic bottlenecks in NS biosynthesis and glycosylation could be expected across cell 
lines, and we can therefore not rule out the effectiveness of these additives on glycosylation 
(showed no effect in our cell line) in other cell lines. Future investigation, testing more cell lines 
with different concentrations and combinations of glycosylation precursors, could help to advance 
our understanding of the metabolic limits of different cell lines. This will aid us to improve current 
strategies for controlling and optimizing glycosylation patterns of heterologously expressed 
biopharmaceuticals.  
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Chapter 5 CHO ‘Omics-based bioprocessing 
Very recently, CHO cell-based bioprocessing entered omics era. How to apply this type of data to 
facility cell line and process development for producing recombinant proteins with higher titer and 
better quality became a challenge. In this chapter, we will present our review paper published in 
Pharmaceutical Bioprocessing, 2014, Vol. 2, No. 5, Pages 437-448, which highlight the status and 
recent update in the field of CHO ‘omics studies and the potential application in genome scale 
modeling of CHO cells.  
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Abstract 
Bioprocessing of the important Chinese hamster ovary (CHO) cell lines for used production of 
biopharmaceuticals stands at the brink of several redefining events.  In 2011, the field entered the 
genomics era, which has accelerated omics-based phenotyping of the cell lines. In this review we 
describe one possible application of this data: The generation of computational models for 
predictive and descriptive analysis of CHO cellular metabolism. We describe relevant advances in 
other organisms and how they can be applied to CHO cells. The immediate implications of the 
implementation of these methods will be accelerated development of the next generation of CHO 
cell lines and derived biopharmaceuticals. 
5.1. Introduction 
It is generally appreciated that cell culture based on Chinese hamster ovary (CHO) cells holds 
substantial economical and medical importance. The global market for biologics was 99 billion 
USD in 2009, where 60-70% of the products were produced in CHO cells [1].  Over 40 
biopharmaceuticals have been produced in CHO cells so far, including monoclonal antibodies, 
hormones, cytokines and blood-coagulation factors. It is furthermore evident that the impact of 
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CHO cell culture will only increase in the immediate future: The US market for biologics alone has 
been climbing from 51.3 billion USD in 2010 to 63.6 billion USD in 2012, and expected to increase 
at higher rates with the US Affordable Care Act [2]. The global market for biologics is expected to 
rise to 190 billion USD in 2015 [3], and the percentage of CHO-derived products in approved new 
biologics are climbing. In 2010 and 2011 combined, 14 out of 19 approved biopharmaceuticals 
were derived from cell culture, the majority of these using CHO cells as hosts [4].  
Despite this impact, the development of CHO cell processes - although highly successful - has been 
mainly driven by medium development and process engineering and to a lesser extent genomic 
technologies such as enhanced expression technologies for heterologous proteins [5]. Metabolic 
engineering, such as seen in microbial cell factories [6,7], has been very limited, although with 
some notable exceptions (see e.g. [8,9]). We will argue that this has been due to the relatively late 
arrival of genome sequences for CHO cell lines; even though the first CHO EST sequences were 
published in 2005 [10], the first CHO genome sequences were published in 2011 [11,12], an entire 
decade after the first draft publication of the human genome [13], and two decades after the genome 
of the first eukaryote, S. cerevisiae [14]. As a result, most early genome-based studies of CHO cells 
were performed by using the genome sequences from other mammals e.g. human, mouse, or rat 
[15,16], which generally limits the possible experiments and interpretation of the results.  
However, there is now ample genomic information available for the CHO cell lines. The CHO-K1 
genome sequence [11], has been supplemented by the 2013 release of two draft genomes for the 
Chinese Hamster (Cricetulus griseus) [17,18] from which the CHO cell line was originally isolated 
in 1957 [19]. Additionally, draft sequences for a number of CHO cell lines including the 
industrially relevant CHO-S and CHO DG44 have been published [18]. While this still leaves a few 
widely used cell lines, e.g. the CHO DXB11 cell line [20,21], unsequenced, and a general need for 
improved genome quality, it is clear that CHO cell research has reached the genomic era. 
One highly promising application of genomics-based research is the generation of genome-scale 
models of CHO cells (Figure 1). 
5.2. Potential Applications of Metabolic Models to CHO Cell Cultures 
A genome-scale metabolic model (GSM) is a systematic correlation of the genomic information of 
an organism to a metabolic network, effectively reconstructing the metabolic network of the cell 
type in question. Such a network is most often built from available generic pathway databases (e.g. 
KEGG [22]) and specific literature for the organism being modeled, combined with an annotated 
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genome [23].This underlying network is often called a genome-scale reconstruction or GENRE. 
Integration of the GENRE with a linear programming-based mathematical framework allows 
modelling of the metabolic fluxes of the cell, which is often predictive and nearly always helpful in 
data interpretation. The actual model and computational framework applies the laws of mass 
conservation and balances of metabolic fluxes around single metabolites to compute enzymatic 
rates for every single enzyme present in the model. These rates are seen as averages for the culture 
and are most often given as specific rates relative to a certain number of cells. Additional 
algorithms may be applied to predict the effect of e.g. gene deletions/insertions, pertubations of 
feeding rates/nutrient uptake or increased production rates (e.g. [24]). Pioneering work and 
additional application such as integration of the protein secretion network and regulatory 
information has been driven forward in E. coli [25–27]. As CHO cells are arguably more complex 
in terms of gene numbers and cellular compartments than E. coli, the work associated with building 
a CHO GSM is more laborious and complicated, in particular in terms of assigning correct genes to 
enzymatic functions, and assigning enzymatic reactions to the correct compartments. However, the 
algorithms and uses of these models are general, and examples of potential applications from E. coli 
are equally relevant for CHO cells. In addition to this, implementation has been performed in a wide 
span of eukaryotic organisms as well, several of which with a complexity and quality of annotation 
resembling CHO cells. Examples of eukaryotic models include eukaryotic microbes, e.g. 
industrially relevant yeasts such as S. cerevisiae, Kluyveromyces lactis, and Pichia pastoris [28–31], 
filamentous fungi applied for enzyme production, e.g. Aspergillus niger [32–34], and also higher 
eukaryotes such as Arabidopsis [35], mouse hybridoma cells [36], and human cells [37,38]. In these 
examples, cells, arguably as complex as CHO cells, have had their metabolism reconstructed. Cells 
from mouse, Arabidopsis, and human are evidently of similar or higher complexity than the CHO 
cell. Even eukaryotic microbes such as filamentous fungi have a more complex growth physiology, 
with multicellular growth compared to the relatively homogeneous CHO cells with a more uniform 
growth. While the current annotation of the CHO genome is far from the quality of annotation and 
gene characterization found for human cells or even mouse cells [39], models can to a large part be 
generated by inferring function by homology to organisms with better annotation, e.g. mouse or 
human in the case of CHO.  
The primary applications of these models can be divided into at least five major categories: 1)  
metabolic engineering, 2) model-directed discovery, 3) interpretations of phenotypes, 4) analysis of 
network properties, and 5) studies of evolutionary processes [40,41]. All of these applications are 
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highly relevant and interesting for CHO cell culture in their omics-driven approach to cellular 
physiology (Figure 1E). 
Metabolic engineering holds considerable promise for CHO cell culture, as GSMs have the 
possibility of predicting the effect of gene deletions, additions and over-/under-expression. Several 
phenotypic traits of the CHO cells are sub-optimal for prolonged culture and protein productivity. 
Some examples of this are the conversion of high glycolytic flux to lactate, or the formation of 
ammonium by conversion of amino acids in the medium. Both are detrimental to cell growth and 
product quality [42,43]. Accordingly, these processes have been subjected to metabolic engineering 
with varying success [8,9], but definitive solutions have not been found at the cell engineering level, 
and have to a large extent been addressed and alleviated with process and medium design (See e.g. 
[44] for an example for lactate production). Model-driven engineering presents an interesting angle 
on these problems, by generating platform cell lines incapable of producing such by-products or 
producing them in highly reduced amounts. Other possibilities are found in areas addressed in 
microbial cell factories, e.g. increasing the number of sugars available for carbon catabolism to 
decrease the problems with high glycolytic flux [45]. GSMs also provide attractive possibilities to 
model decreased by-product formation [46], generally applicable to any biotechnological 
production process. Another tantalizing possibility is the extension of the significant advances in 
CHO culture medium development [5]. One could imagine that it would be interesting to perform 
model-guided systemic cell line engineering to tailor the cell lines to a specific medium, or a certain 
feeding profile. The capabilities of GSMs to model cellular metabolism on a systemic scale, allows 
the combination of e.g. consumption rates of medium components with model predictions.  The 
result of this would be further improvement of platform media and processes with a tailored cell 
line. 
Model-directed discovery has been useful in many microbial systems, in particular for improving 
gene annotation and functional assignment [32,33,41]. With the current state of CHO genomics 
being in its infancy, the annotation of the identified genes is very preliminary. The state of the CHO 
genome annotation on one hand complicates accurate model reconstructions, due to the challenges 
of linking genes with function, but also presents opportunities. In particular the reconstruction of 
CHO metabolism (GENRE) will suggest tentative assignment for a high percentage of the 
metabolic genes, as is seen in other eukaryotic microbes organisms [28,32,34], where the genes 
involved in metabolism have not been studied as extensively as in leading model organisms e.g. 
yeast or E. coli [25,29]. However, even in E. coli has the metabolic network been applied to find 
and characterize candidate genes for a specific function [47]. This type of application of the 
78 
 
metabolic network is particularly powerful when combined with other omics-data types such as 
metabolomics and proteomics (see below). Here one can e.g. integrate orphan metabolites into the 
metabolic network and thus improve our understanding of CHO metabolism, or identify active 
isoenzymes for specific pathways from protein expression data coupled with tentative metabolic 
enzyme networks.  As this application of the model is fairly independent of the computational 
predictive power, it is relevant to CHO cells no matter how accurate the models might become. The 
same holds true for the next application: 
Interpretation of phenotypes is perhaps the most universally applicable use of the GSMs and 
GENREs. The network – irrespective of predictive power – provides a framework for interpretation 
of experimental data. For CHO cells, the calculation of metabolite consumption/production rates, 
growth rates and specific product formation rates has long been standard for cell culture medium 
and process design. However, a theoretical and computational framework for holistic interpretation 
of the data has not previously been available. These reconstructed networks can aid the 
interpretation of experimental data related to growth, as well as multiple types of omics data [41]. 
Models have proven important in interpretation of metabolic/flux data [48], transcriptomics [49], 
and proteomics [50]. The approaches are listed in an excellent recent review [51], which also covers 
mammalian cell types. A related example from medical research is the interpretation of proteomic 
and DNA microarray data from human macrophages through a reconstructed metabolic network of 
the cell type [38]. In this study, a holistic view of the process of activation of macrophages was 
achieved, and systemic activation and inactivation of parts of metabolism was identified. 
In many cases, models are also capable of quite persuasive prediction of phenotypes. Especially 
interesting, considering the costs and time required to produce stable genetic changes in CHO cells, 
is prediction of phenotypes of genetic mutants [52,53]. 
Analysis of network properties is generally speaking a computational exercise, in which one 
analyzes the network structure of the GENRE to discover inherent features or emergent properties 
of the metabolic network. In some cases, this analysis has become mainly an arithmetic exercise, 
applying standard network topology algorithms, and has generated limited biological insight. 
However, in some cases, deep insights are found. The most easily applicable example in the context 
of CHO cell and process engineering, is the application of elementary flux modes [54] to identify 
the smallest possible set of essential metabolic genes in CHO cells, such as achieved for individual 
pathways in E. coli [55] or S. cerevisiae [56]. Such identification could be applied for generating 
cell lines with a trimmed metabolism, thus decreasing the variability of the system. This would be 
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feasible for CHO, despite the presence of extra isoenzymes or alternate pathways in many 
enzymatic steps. For several enzymatic functions, only one of the isoenzymes are detected at the 
protein level [57]. Alternatively, one can delete steps in the enzymatic pathways/elementary flux 
modes, where only one enzyme exists. 
Studies of evolutionary processes have been a re-occurring theme in several applications of 
bacterial network, in particular the E. coli GENRE [40,41]. In such studies, specialized models have 
e.g. been developed to describe specific strains of E. coli, and compared these to identify the genetic 
origin of specific phenotypes [58]. Given the availability of the genomic sequence for multiple 
CHO cell lines with varying properties [18] and surely more to come, such an exercise would hold 
exciting perspectives for interpreting these genomes. One possible application would be the genetic 
basis for certain metabolic features in cell lines generated by mutagenesis, and the possibility of de 
novo engineering the features into a "clean" background. This would reduce possible complications 
from decreased genetic stability in mutants subjected to mutagenesis [59]. 
With the above-mentioned being only a small percentage of the possible applications of such 
models for CHO cell lines, the potential is clearly large for the generation and application of 
GENREs and GSMs for CHO cells. 
5.3. Additional Available Data Sources for Increased Applicability of CHO 
Models 
The availability of an annotated genome for CHO cells is the bare minimum of information required 
to generate a draft model for CHO cells. Models of microbial systems have been published based 
mainly on literature on characterized genes (e.g. for Corynebacterium glutamicum [60] or 
Aspergillus niger [32,61]), but this requires detailed legacy data for a wide selection of metabolic 
pathways. In general, most recent generation of GSMs is based on variations of a standardized 
protocol for metabolic network reconstruction and model validation published in 2010 [23], using 
basic genome annotation as a starting point for the organism of choice. 
However, other types of omics data have proven highly valuable for model generation, validation 
and application. Here, the CHO field is maturing at an impressive pace, considering the quite recent 
publication of the first public CHO genome [11], followed by a wealth of other omics types being 
published in these years [62]. Here we will briefly emphasize selected studies which provide data 
highly applicable to CHO modelling, either due to the experimental setup of the study, the type of 
the data, or the perspectives these offer for CHO modeling. Several of these data types are discussed 
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in detail in other reviews in this issue, to which we direct the reader interested in further depth on 
specific data types [Add reference(s) in Proof]. 
5.3.1. Genomics 
A well-annotated genome with a high coverage is a crucial component in building a GSM with 
predictive power or a GENRE with a potential for informative data integration and interpretation. It 
is essential to be able to identify the genes of all major metabolic pathways in order to generate an 
accurate GENRE and following that a GSM. This requires a genome coverage of ideally >99% of 
the genes. Early EST sequencing efforts [10] identified only less than 20% of the genes, shown to 
be present in the  CHO-K1 cell line draft genome [11]. Convenient for model construction, the 
genome sequence has been made accessible at the online database www.CHOgenome.org [63] as 
well as at the NCBI genbank. The coverage appears to be at least 99%, at least it was demonstrated 
that homologs existed for 99% of the genes in the human genome associated with glycosylation.  
Due to the variability of the cell lines, it can be argued that it would be most appropriate to use the 
progenitor Chinese hamster (C. griseus) both as the source of a reference genome, and as a scaffold 
for a master CHO GSM, from which specialized models can be generated for individual cell lines. 
This is now possible due to the publication of draft genomes for C. griseus [17,18]. This publication 
showed that there are more than 3.7 million point mutations between the progenitor hamster and the 
CHO cell lines [18] and extensive chromosomal rearrangements that has occurred between CHO-
K1 and CHO-DG44 [64] emphasizing the effects of the mutagenesis that occurred in the process of 
creating the various cell lines. Currently, in order to fully exploit these sequences, these genomes 
must be mapped against reference genomes with gene annotation. Improving the gene annotation 
for the C. griseus genome and CHO-K1, which has become the de-facto reference genome for cell 
lines, would be beneficial to model building. Current and new genomes could thus be aligned to 
these references for detection of mutations. 
Furthermore, the state of genome assembly should be improved. Currently the genomes for both 
hamster and cell lines are divided into at least 4000 contigs per genome, which means that genes for 
important metabolic functions may be lost in the sequencing gaps. Such gaps can to some extent be 
detected and fixed in the network reconstruction process [23,32]. Even so, an appropriate solution 
would be to apply 3
rd
 generation sequencing to yield longer sequenced reads that can assemble the 
contigs to improve the coverage of the genomes. Such efforts are in progress in the community 
(Prof. Nicole Borth, personal communications), and should have a substantial positive impact on the 
models, which can be constructed for CHO cells. 
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5.3.2. Transcriptomics 
In general, it is only a low percentage of the CHO genes which are actually expressed under normal 
condition, e.g. only ~50% of the genes involved in protein glycosylation are transcriptionally active 
[11]. Consequently, integration of dynamic omics-data such as transcriptomics and proteomics are 
important for accurate prediction of gene deletion/silencing effects. Several studies and tools are 
now available for this, including both sequencing and DNA microarray based methods. Naturally, 
some of the first transcriptome data was generated prior to the genome sequence based on EST 
sequences from CHO and mouse used for design of microarrays [65,66]. 
Worth particular mention is a large-scale comparison of microarray data from more than 120 
individual CHO cultures [67]. The data can be accessed through the web-based CHO gene co-
expression database (CGCDB) allowing easy access to the list of genes found to co-express with e.g. 
cell specific productivity and growth rate. Such data could be used for model improvement and 
validation. For easy and relatively inexpensive assessment of the CHO transcriptome in future 
experiments, a new generation of the Affymetrix CHO DNA microarray has been launched with up 
to 26 unique sequences of each transcript with a total of more than 644,000 probes [68]. 
RNA-sequencing is expanding for CHO culture as in many other fields [69]. Recently, a 
transcriptome database for CHO RNA sequencing data has been developed and is available at 
https://gendbe.cebitec.uni-bielefeld.de/cho.html [70].  
In summary, transcriptomics data is abundantly available, and will only increase in the coming 
years. 
5.3.3. Proteomics 
The CHO proteome is interesting in the context of CHO metabolic modelling as it can provide 
additional functional information, in some cases expanding on transcriptomic evidence. The 
proteome of CHO-K1 was thoroughly characterized by Baycin-Hizal in 2012 [57]. Here, 6164 
proteins were detected. Of these, only 60% were also detected at the mRNA level by Xu in 2011 
[11]. The functional application of the data and the need for having models specialized to individual 
cell lines becomes apparent from this study. Statistical analysis indicated that some pathways such 
as fatty acid metabolism, amino sugar and nucleotide sugar metabolism, which provide important 
precursors for recombinant protein synthesis, as well as protein processing and apoptosis, were 
enriched in CHO-K1 [57]. 
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Given the principal application of CHO cells for production of secreted proteins, in this content, 
secretome data, such as characterized from the CHO DG44 and CHO-S cell lines by Slade [71], is 
interesting to incorporate. Such data can help identify secretory bottlenecks or extracellular 
proteases as seen for microbial cell factories [72,73]. 
CHO specific protein databases have been constructed based on data from the CHO-K1 genome [11] 
and the CHO transcriptome [74], and have been shown to increase the number of identified proteins 
by 40-50% from proteomics studies compared to only using protein databases based on e.g. the 
murine proteome [75]. 
It is generally accepted that the generation of proteomics data is more technically challenging than 
transcriptome data, but the pilot studies within CHO cells, such as those mentioned above, show 
that there is clearly additional value to be gained from interrogating this data set.  
5.3.4. Metabolomics 
As mentioned in the text above, metabolomics has considerable value to add in the model building 
process, as this type of data can help identify metabolic pathways, which are experimentally shown 
to be occurring in the cells due to the presence of metabolic intermediates or products, but the 
genetic basis is not necessarily clear. Being able to identify and include these pathways can increase 
the predictive power of the model.  
For such inclusion, several studies of high quality [76,77] and standardized protocols [77–80] have 
been available for several years, as metabolomics are not as such dependent on the availability of a 
genome. 
Two studies are of particular interest in terms of getting data of a sufficient quality for model 
integration. The first was published by Dietmair et al [81] correlating intracellular and extracellular 
metabolite concentrations with growth. The second is the work of Chong et al [82] where 
intracellular metabolite profiles were obtained for eight single cell clones with high and low qmAb at 
the mid-exponential phase during shake flask batch cultures. Such studies can give insight in 
metabolic responses, and help validate CHO metabolic models, in that one can examine and adapt 
the ability of the model to predict these responses. 
The application of the metabolic networks to interpret metabolomics data, can also be exemplified 
in a 2012 study by Selvarasu et al [83], where a generalized metabolic network of mammalian cells 
was adapted to CHO cells to aid in metabolomics data interpretation (see further details below). The 
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coupling of the network, genome-scale-modeling, and metabolomics data allowed the identification 
of growth-limiting factors. 
Overall, the CHO field is at this point uniquely poised to utilize the substantial amounts of available 
omics data in building high quality models for CHO cells. An overview is presented in Figure 1. 
During any future model building efforts, one should draw upon the current availability of 
computational models for CHO and similar systems, and incorporate this where appropriate. 
5.4. Overview of Cellular Modelling Efforts in CHO cells and Beyond 
So far, no dedicated effort to building a CHO GSM de novo has been published. The closest 
example is the adaptation of a model of mouse hybridoma cells [36] to CHO cells by the addition of 
35 CHO-specific metabolic reactions and subsequent model curation resulting in a model 
comprising 1,540 reactions and 1,302 metabolites [83]. This model has been further developed by 
other groups, although not published through a journal at this time, but is available for download 
from http://cho.sourceforge.net/. A similar approach of adapting a mouse GSM was employed by 
Martínez et al [84] for examining the energy consumption and metabolism surrounding lactate 
formation and consumption in CHO cells. 
Dedicated models have been developed for related cell lines in other systems, as mentioned a 
generic model for mouse cells, applied to mouse hybridoma cell lines [36], and a model for the 
HEK-293 cell line has been developed as well [85]. This study is particularly promising for CHO 
cell modelling, as the HEK-293 model was developed by reducing the generic model for human 
cellular metabolism [37] to a model specific for HEK-293 metabolism. Furthermore, this model was 
employed to interpret both transcriptomic, metabolomic, and flux data to gain functional 
understanding of glucose and glutamine metabolism; both key features for CHO metabolism [85]. A 
similar study has been seen for BHK cells for interpretation of metabolomics data [86]. 
These models listed above represent the full list of available metabolic genome-scale models with 
relevance to CHO cells. However, to the best of our knowledge, a model specific for CHO cells, or 
any specific cell line has still have not been generated. 
One area, where modelling in CHO cells is more developed, is the kinetic modelling of protein N-
glycosylation, in particular integrated with mass spectrometry on glycans. Here, very accurate 
predictions and substantial networks have been generated and improved over the last two decades. 
The first mathematical model for protein N-glycosylation process was built in 1997 by the 
complementary studies of a single-compartmental model [87] and a multi-compartmental model 
84 
 
[88]. Later work expanded upon the previous work to involve glycosylation processes as 
galactosylation, fucoslation, sialylation, and addition of N-acetyllactosamine residues [89]. This 
model had up to 7,565 N-glycans and 22,871 reactions included. Furthermore, two glycosylation 
models based on different views of protein transport across the Golgi, namely Golgi maturation 
mechanism and vesicular transport mechanism, were studied and compared. This model was highly 
expanded and sophisticated by the same group to include interpretative power of N-glycan MS data 
[90]. More recently, an optimized model considering 77 N-glycans, 8 enzymes, 4 nucleotide 
transporters and 95 reactions with individual rate expressions were built on the basis of Golgi 
maturation mechanism with an improvement of taking Golgi protein recycling into account [91]. On 
top of that, a more comprehensive glycosylation model that link a model that described the 
metabolism of nucleotides and nucleotide sugars to the previous N-glycosylation model was 
developed by the same group [92]. These networks have been shown to have both high predictive 
and interpretative power, and would be unique key features to have integrated in CHO GSMs, to the 
extent that it is possible. Such additions could predict effects of glycosylation engineering and/or 
the effect of different substrate uptake rates. 
5.5. Future Perspectives 
With the potential of GSMs tailored to CHO cells as demonstrated above, it is not surprising that 
several groups in the CHO community are working on building whole and partial reconstructions of 
CHO metabolism, including some of the authors of this review. These groups have this year formed 
a consortium compiling their work, and are working towards generating a community consensus 
model for CHO cells (Nathan E. Lewis, personal communications). Such models and network 
reconstructions are known from several other research communities, including Salmonella 
Typhimurium [93], yeast [29,94], and human [37] metabolism. 
The future arrival of the CHO GSM will probably raise the same discussion that followed the 
release of the first CHO genome: How well does this model describe each of the different CHO cell 
lines? Each of the cell lines have undergone rearrangements and have diverse transcriptomes and 
for this reason several parameters will need to be investigated. Future and current sequencing 
projects for individual cell lines should be combined with bioreactor characterization of the cell 
lines and their corresponding models to gain a functional understanding of the differences (Figure 
1C-D). The next years will tell whether these models will be able to model the complex behaviour 
of the CHO cell and open up new design targets such as it has been the case in microbes. Making 
such specialized models will be a substantial amount of work, but this task will be made easier, if a 
85 
 
generic CHO model of high quality based on an assembled and annotated reference genome is 
generated first. From that, specialized models can be made in semi-automated fashion through 
comparative genomics. This would have the additional advantage, that annotation of the genomes of 
the individual cell lines would not be required (as this is currently not available [18]), but could be 
achieved by alignment to the reference genome. 
Should the models be able to deliver on the promise and potential seen in other cells, it is bound to 
trigger a second wave of CHO cell line engineering. Notably CRISPR Cas9-based genome editing 
systems being made available at non-cost prohibitive prices [95] and efficient high-through-put 
mammalian vector design systems [96], support the development of faster and cheaper genome 
engineering tools to accelerate future cell line engineering efforts in CHO. 
In summary, the potential of genome-scale models stands to be unleashed in CHO cells within a 
very short time span. Combined with the genomes ushering in the genomics era for CHO, 
substantial amounts of omics-data is being generated, and the development of efficient genetic 
engineering tools, CHO cell culture will soon move into the next generation of cell line 
development. Such advances promise better and cheaper development of biopharmaceuticals for 
this important group of cell factories. 
5.6. Executive Summary 
 Genome-scale metabolic models have been applied with success in many other prokaryotic 
and eukaryotic cell factories. 
 The CHO field now has all of the relevant information and methods needed to construct and 
apply such models. 
 A CHO metabolic model will have applications both in design and engineering of cells, but 
equally important also in interpretation of omics-data. The potential is large. 
 Initial CHO models have adapted from models of mouse metabolism, but no de novo CHO 
models have been published at this time. 
 The community is currently constructing a consensus model for CHO metabolism. 
 Added value will come from generating specialized models for individual cell lines.  
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Figure 1 - Model building and application in CHO cells. A) Initial drafting of a genome-scale metabolic 
model (GSM) requires genomic annotation supplemented with available literature and knowledge on the 
metabolism of choice. This generates a draft genome-scale metabolic network reconstruction (GENRE). B) 
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Multiple iterations of model improvement and testing, supplemented with available omics and phenotypic 
data generates a GSM capable of computation.  C) A generalized GSM for CHO cells can be tailored to 
specific cell lines (D) by the inclusion of additional omics data specific for the individual cell lines. E) Both 
generalized and specialized CHO GSMs may be applied to engineer cell lines, interpret data and increase 
functional understanding of these important cell lines. 
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Abstract 
In this study, systems biology tools were used to explore the effect of glucose starvation and culture 
duration on monoclonal antibody (mAb) production in fed-batch CHO cell culture to gain better 
insight into how these parameters can be controlled to ensure optimal mAb productivity and quality. 
Titer, N-glycosylation and charge heterogeneity of mAbs, as well as proteomic signature and 
metabolic status of the production cells in the culture were assessed.  
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We found that the impact of glucose starvation on the titer, N-glycosylation and charge 
heterogeneity of mAbs was dependent on the degree of starvation during the stationary phase of the 
fed-batch culture. Higher degree of glucose starvation reduced intracellular concentrations of UDP-
GlcNAc and UDP-GalNAc, but increased the levels of UDP-Glc and UDP-Gal. Increased GlcNAc 
and Gal occupancy correlated well with increased degree of glucose starvation, which can be 
attributed to the interplay between the dilution effect associated with change in specific productivity 
of mAbs and the changed nucleotide sugar metabolism. 
Herein, we also show and discuss that increased cell culture duration negatively affect the 
maturation of glycans. In addition, comparative proteomics analysis of cells was conducted to 
observe differences in protein abundance between growth and stationary phases. Generally higher 
expression of proteins involved in regulating cellular metabolism, extracellular matrix, apoptosis, 
protein secretion and glycosylation was found in stationary phase. These analyses offered a 
systematic view of the intrinsic properties of these cells and allowed us to explore the root causes 
correlating culture duration with variations in the productivity and glycosylation quality of 
monoclonal antibodies produced with CHO cells. 
6.1. Introduction 
Over the last decade Chinese hamster ovary (CHO) cells have been the predominant expression 
system used in the pharmaceutical bioprocessing of recombinant monoclonal antibodies (mAbs) 
due to their adaptability to industrial manufacturing environment and post-translational 
modification compatibility with human patients (Lim et al. 2010). Fed-batch culture has become a 
widely used approach for mAb production because of its value in extending the viable and 
productive phase of the culture (Rouiller et al. 2013).  
The manufacturing process is typically optimized for increasing the productivity of mAbs, but this 
often increases the risk of compromising the critical quality attributes of the recombinant product. A 
number of strategies aiming at improving final titer have been proposed. For example, limiting the 
feed of glucose to minimize lactate accumulation (Dean and Reddy 2013; Gagnon et al. 2011) and 
extending culture duration to prolong the production window (Druz et al. 2013; Robinson et al. 
1994), have been successfully implemented. However, all these strategies require precise control of 
the production process. The level of glucose limitation is crucial for the process, since it may cause 
undesired glucose starvation and lead to reduced cell growth and productivity (Hu et al. 1987) and 
altered N-glycosylation quality (Liu et al. 2014). Extended culture duration may also affect the mAb 
quality in terms of N-glycosylation patterns (Pacis et al. 2011) and charge heterogeneity (Kaneko et 
al. 2010). 
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N-glycosylation of mAbs affects their pharmacokinetic characteristics and efficacy as a drug, 
including clearance rate, stability, immunogenicity, antibody-dependent cellular cytoxicity (ADCC) 
and complement-dependent cytoxicity (CDC) (Goetze et al. 2011; Hossler et al. 2009; Jefferis 2012; 
Raju 2008; Zheng et al. 2011). A further quality criterion is the charge heterogeneity of the mAb, 
which provides information concerning net surface charges and conformational structure of the 
mAbs. Charge heterogeneity may be affected by different types of post-translational modification, 
such as N-glycosylation (mAbs with more processed glycans appear as more acidic forms), C-
terminal lysine processing (processed mAbs appear as more acidic forms), deamidation (deamidated 
mAbs appear as more acidic forms), and oxidation (oxidated mAbs appear as more basic forms) 
(Chumsae et al. 2007; Hong et al. 2014; Liu et al. 2006; Perkins et al. 2000).  
Recently, CHO cell bioprocessing entered the omics era (Kildegaard et al. 2013), thanks to the 
availability of the CHO-K1 and Chinese hamster genome sequences, along with draft genomes of 
multiple cell lines (Cao et al. 2012; Lewis et al. 2013; Xu et al. 2011). This has made other omics-
based technologies more readily available for CHO cell culture, including RNA-sequencing 
transcriptomics analysis (McGettigan 2013) and tandem mass spectrometry-based proteomics 
analysis (Baycin-Hizal et al. 2012). In order to increase the understanding of CHO cell physiology 
to better control the quality attributes of mAbs, systems-biology based approaches that integrate 
data from cell culture behavior, metabolism, mAb quality and omics-based phenotyping will 
become a trend for CHO cell culture process development in the future. 
This study is, to our best knowledge, the first time a multi-pronged approach has been used to 
investigate the effect of glucose starvation and culture duration on mAb production in fed-batch 
CHO cell culture. Here, we aim to understand how the titer, N-glycosylation and charge 
heterogeneity of the mAb product, as well as the proteomic signature and the intrinsic properties of 
the cells, are affected by changing these process parameters. The results presented herein provide 
mechanistic insight into how these process parameters influence mAb productivity and quality, and 
thus should aid in the identification of an appropriate operating windows for glucose limitation 
without running into glucose starvation and of the optimal harvest time. 
6.2. Materials and methods 
6.2.1. Cell culture and fed-batch process 
Cell line A, an in-house CHO DG44 cell line producing mAb A was used as model cell line in this 
study. Cells were maintained in proprietary serum-free basal medium in shake flask at 37˚C, 5% 
CO2, 200 rpm prior to the fed-batch process.  
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Fed-batch culture was carried out in 500 ml shake flasks (working volume 50 – 100 ml) at 37°C, 5% 
CO2, 200 rpm with an initial seeding density of 4×10
5
 viable cells/mL and temperature shift from 
37°C to 33.5°C on day 5. Proprietary feed was added to the culture on days 2, 5, 7, 9 and 12 (10% 
of the initial culture volume). Glucose concentration was adjusted to 33mM on day 5 and to 50mM 
on day 12. Cell culture was sampled before feeding on days 2, 5, 7, 9, 12 and 14 for monitoring cell 
growth (Vi-CELL XR, Beckman Coulter, Brea, CA), cell metabolism (Bioprofile 100plus, Nova 
BioMedical, Waltham, WA) and mAb production (Octet QK384 equipped with Protein A 
biosensors, ForteBio, Menlo Park, CA). Sampling for intracellular nucleotide sugar quantification 
and mAb glycoprofiling was performed on days 2, 5, 9 and 12. Harvesting criteria for the culture 
was considered to be either when cell viability fell below 70% or on day 14, whichever occurred 
first. Four different fed-batch processes were performed in duplicate: severe glucose starvation 
(SGS), high glucose starvation (HGS), low glucose starvation (LGS) and no glucose starvation 
(NGS). In each of these processes, glucose concentration was set to 11mM (SGS), 22mM (HGS), 
33mM (LGS) and 50mM (NGS) on day 9 of the fed-batch culture. Additional sampling for 
comparative proteomics analysis was performed on days 2 and 9 of the NGS process. 
6.2.2. Nucleotide sugar analysis 
Nucleotide sugar analysis was performed on harvested cell pellets using acetonitrile extraction 
followed by high-performance anion-exchange (HPAEC) HPLC as described previously (Fan et al. 
2014; Jimenez Del Val et al. 2013).  
6.2.3. Semi-high throughput mAb purification 
The supernatant harvested from cell culture was filtered through a 0.22μm filter (Millipore, 
Billerica, MA) and applied onto a Protein A HP MultiTrap™ 96-well filter plate (GE Healthcare, 
Fairfield, CA) which had been previously equilibrated with PBS following the manufacturer's 
instructions. Elution was performed using 0.1M citrate buffer (pH=3.5, Sigma-Aldrich). The eluate 
was immediately transferred to a Zeba™ spin desalting plate (Thermo Scientific, Waltham, MA) 
previously equilibrated with a 10mM citrate, 150mM NaCl (pH=6.0) buffer (Sigma-Aldrich, St. 
Louis, MO). Purified mAb concentration was measured using a NanoDrop ND-1000 system 
(Thermo Scientific) prior to sample storage at -20°C. 
6.2.4. Cation-Exchange chromatography 
10μg purified mAbs were subjected to Cation-Exchange chromatography (CEX) on a ProPac 
WCX-10 column (250 x 4 mm, Dionex, Sunnyvale, CA) fitted to a Dionex HPLC system equipped 
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with UV detection set at 280nm. The flow rate was set to 1mL/min with a linear gradient (T0 min =5% 
B, T6 min=5% B, T22 min=100% B, T38 min =100% B, T38,1 min = 5% B, T47 min = 5% B) between solvent 
A (25mM sodium acetate, pH =5, Sigma-Aldrich) and solvent B (25mM sodium acetate, 0.5M 
NaCl, pH=5, Sigma-Aldrich). The shoulders of the heterogeneous peak obtained with CEX 
chromatography are identified as acidic, main, basic 1 and basic 2 mAb isoforms depending on the 
order in which they appear (Figure 1S, from left to the right) and can be quantified individually. 
6.2.5. mAb Glycoprofiling 
mAb Glycoprofiling was performed with an in-house HPLC analysis method using InstantAB 
labeled (Prozyme, Hayward, CA) glycans (Fan et al. 2014). 
6.2.6. Statistical analysis of glycoform distributions 
Differences among the glycoform distributions were evaluated by comparing the mean obtained 
from two independent experiments. Depending on equality of variances, different post-hoc tests 
were performed to assess the statistical significance of the differences among the means. First, the 
variances of each treatment were compared using Levene’s test. If the variances were observed to 
be equal, a one-way ANOVA was performed to evaluate the differences between the means of the 
treatments. Where the ANOVA yielded statistically significant differences (pANOVA<0.05), Tukey’s 
honestly significant difference test was performed post-hoc for pairwise comparisons. For data 
where the variances were found to be unequal, a one-way Welch’s ANOVA was performed, and if 
this analysis yielded statistical significance (pWELCH<0.05), the Games-Howell post hoc test was 
performed for pairwise comparisons. All statistical analysis was performed using the IBM SPSS 
Statistics software, v.20 (SPSS Inc. 2011). 
6.2.7. Sample preparation for proteomics analysis 
Two biological replicates from days 2 and 9 of the NGS fed batch process were subjected to 
proteomics analysis using iTRAQ (isobaric Tags for Relative and Absolute Quantification) labeling 
mass spectrometry (Aggarwal et al. 2006; Pottiez et al. 2012). The harvested cells were washed 
with ice-cold PBS (Invitrogen, Life Technologies, Carlsbad, CA), flash-frozen in liquid nitrogen 
and stored at -80°C prior to cell lysis.  For lysis, the cells were thawed and immediately 
resuspended in SDS-lysis buffer (2% SDS (w/v), 1mM EDTA and 0.1mM phenylmethylsulfonyl 
fluoride [PMFS], pH = 8 adjusted with triethylammonium bicarbonate [TEABC], Sigma-Aldrich) 
and sonicated on ice three times for 30 seconds with a probe sonicator. The total protein 
concentration of the lysate was measured with the BCA assay (Thermo scientific).  
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The lysates were then reduced by incubation in a final concentration of 4.5mM Tris-(2-carboxyethyl) 
phosphine (TCEP, Sigma-Aldrich) at 60°C for 1 hour and subsequently alkylated by incubation in a 
final concentration of 8.3mM methyl methanethiosulfonate (MMTS, Sigma-Aldrich) at room 
temperature in the dark for 30 min using a modified filter-aided sample preparation (FASP) 
protocol based on Wisniewski et al. (2009). 90µg of the obtained protein from each sample were 
diluted with 9M Sequanal grade urea (Thermo scientific) to obtain a final SDS concentration of 
0.09% (w/v). This mixture was incubated at room temperature in the dark for 1 hour after which the 
low-molecular-weight substances were removed by ultracentrifugation using a 10KDa cutoff 0.5ml 
Amicon filter (Millipore). The retained proteins were digested by incubation with 50µL of LysC 
digestion buffer (50 mM TEABC, pH=8) containing 4.5 µg of LysC enzyme (Wako Pure Chemical 
Industries, Japan) at 37°C for 4 hours and additional incubation with 350µL trypsin LysC digestion 
buffer (50 mM TEABC, pH=8) containing 10 µg trypsin enzyme (Promega Corporation, Madison, 
WI) at 37°C overnight. The digested peptides were dried using SpeedVac (Savant, Thermo 
Scientific) prior to iTRAQ labelling. The iTRAQ 8-plex reagent was dissolved in 50μL of 
isopropanol following the manufacturer's instructions (AB Sciex, Framingham, MA). Each dried 
peptide sample was dissolved in a mixture of 17µL H2O, 20µL 0.5M TEABC and 50µL of iTRAQ 
8-plex reagent solution and incubated for 2 hours at room temperature in the dark. Peptides from 
different samples with their unique iTRAQ labeling were mixed, dried and resuspended into 1mL of 
10mM TEABC prior to peptide fractionation using basic pH reversed-phase liquid chromatography 
(bRPLC). 
6.2.8. Fractionation of peptides  
The bRPLC method was performed to improve identification of unique peptides in the sample as 
was described by Baycin-Hizal et al. (2012). Peptides were fractionated on an XBridge C18 
Column (5 µm, 2.1 x 100 mm, Waters, Milford, MA) with an XBridge C18 Guard Column (5 µm, 
2.1 x 10 mm, Waters), using an Agilent  HPLC system consisting of a 1100 series binary pump, a 
1200 series UV detector and a 1200 series micro-fraction collector. Fractionation of peptides was 
carried out by a linear gradient (T0 min =10% B, T10 min=10% B, T50 min=35% B, T50.1 min=70% 
B, T60 min =70% B, T60,1min = 100% B, T70 min = 100% B, T70.1 min = 10% B, T95 min = 10% 
B) between solvent A (10 mM TEABC, Sigma-Aldrich) and solvent B (10 mM TEABC in 90%v/v 
Acetonitrile, Sigma-Aldrich) with a flow rate of 250µL/min. 84 bRP fractions were collected and 
re-combined into 24 fractions and then dried in a SpeedVac (Savant, Thermo Scientific) prior to 
liquid chromatography/tandem mass spectrometry (LC-MS/MS) analysis. 
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6.2.9. LC-MS/MS analysis 
The LC-MS/MS analysis of the different fractions of the peptides was performed using an LTQ 
Orbitrap Velos MS/MS in FTFT (Thermo Scientific) interfaced with a 2D nanoLC system 
(Eksigent, AB Sciex), as described previously (Baycin-Hizal et al. 2012), but with the following 
modified parameters. Precursor and fragment ions were explored in tandem MS analysis at a 
resolution of 30000 and 15000, respectively. Survey scans (full ms) were acquired on the Orbitrap 
within an m/z range between 350-1700Da. Precursor ions were individually isolated with a 1.2Da 
window and fragmented (MS/MS) using 40% collision energy in order to achieve higher collision 
dissociation (HCD) activation. The MS/MS spectra were analyzed using the Mascot software 
(v2.2.2, Matrix Science, London, UK) in the framework of ProteomeDiscoverer v1.4 (PD1.3; 
Thermo Scientific) with fixed modifications of N-terminal 8-plex-iTRAQ labeling and cysteine 
methylthiolation and variable modifications of methionine oxidation and 8-plex-iTRAQ labeling of 
tyrosine and lysine. 
6.2.10. MS data analysis 
The obtained MS data was compared against the cricetulus_g_v2 custom database, which was 
constructed using the RefSeq annotation of the CHO genomic sequence downloaded in October, 
2013. Protein identification was performed using Mascot v2.2.2 (Matrix Science) where the 
searches were processed with a confidence threshold of 1% False Discovery Rate (FDR). Protein 
ratios were calculated based on the median value of the unique peptide ratios. 
6.2.11. Comparative proteomics analysis  
A BLASTp search of all identified proteins was performed against the mouse, human and rat 
RefSeq databases (accessed on November, 2013) in order to find the closest homologous proteins 
(lowest E-value) in these species. Identifiers, including RefSeq Protein Accession, ENSEMBL gene 
ID, UNIPROT accession and Agilent ID for each protein were subsequently obtained using the 
Gene ID conversion Tool from the DAVID database (Huang da et al. 2009a; Huang da et al. 2009b) 
(from November, 2013). Gene set enrichment analysis (GSEA) (Subramanian et al. 2005) was 
performed on the proteins that exhibited differential expression between days 2 and 9. The resulting 
data were used to identify the up and down-regulated gene sets (between 15 and 500 genes per set) 
between days 2 and 9 of the NGS fed-batch process. This analysis was performed using both the 
functional database (a combination of Biocarta, KEGG and Reactome databases) and the gene 
ontology database (downloaded from Molecular Signatures Database v4.0, 
http://www.broadinstitute.org/gsea/msigdb/index.jsp). Leading edge genes (genes that are core 
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representatives of their gene set with FDR q-value cutoff of 0.25) were identified using Leading-
edge analysis. An enrichment map (Merico et al. 2010) of the gene clusters were obtained in 
Cytoscape v3.1.1 using the GSEA results as input, a p-value cutoff of 0.05 and an FDR q-value 
cutoff of 0.25. A direct search using all identified proteins from MS analysis against an in-house 
reconstruction of the CHO secretory pathway network (Table S8) was performed with a log2 
expression cut off of ±0.8 and a p-value cutoff of 0.05 in order to analyze the secretion machinery 
of the cells. Moreover, all identified proteins that are involved in nucleotide sugar biosynthesis 
pathway and glycan biosynthesis pathway were sorted out and evaluated. 
6.3. Results and Discussion 
During fed-batch manufacturing of mAbs, glucose concentration and culture duration are 
considered to be critical parameters for both productivity and quality (Pacis et al. 2011; Xie et al. 
1997). Therefore, lack of control in these parameters is always risky for mAb manufacture. Here, 
we investigate the effect of glucose starvation during the stationary phase of fed-batch culture and 
the effect of culture duration on mAb productivity, glycosylation and charge heterogeneity. Our 
results contribute to further understand how glucose starvation and culture duration impact CHO 
cell physiology in fed-batch culture processes and yields insight into potential metabolic and/or 
proteomic causes for these effects. 
6.3.1. Effect of glucose starvation 
Culture performance and mAb productivity of four culture processes with different degrees of 
glucose starvation (SGS, HGS, LGS and NGS) are shown in Figure 1 and are summarized in Table 
I. As would be expected, glucose starvation during the stationary phase resulted in earlier onset of 
cell death (Figures 1 A and B), reduced integral viable cell concentration (IVC) (Figure 1 C), lactate 
depletion (Figure 1 E), and increased accumulation of NH4
+
 (Figure 1 F). Additionally, the level of 
glucose starvation negatively correlated with mAb titer (Figure 1 C) and specific productivity (qp) 
(Figure 1 C slope of the curves).  
Table I. Culture performance and mAb production under glucose starvations. * Control. 
Process 
name 
Description Glutamine Glutamate Lactate NH4+ 
Culture 
process 
mAb 
production 
NGS* No glucose starvation Not consumed Highly consumed 
Almost not 
consumed 
Consumed Uninterrupted Uninterrupted 
LGS Low glucose starvation Consumed Highly consumed 
Consumed and 
depleted 
Produced Uninterrupted Reduced 
HGS High glucose starvation Highly consumed Consumed 
Highly consumed 
and depleted 
Highly 
produced 
Early-ended Highly reduced 
SGS Severe glucose starvation Highly consumed Consumed 
Highly consumed 
and depleted 
Extremely 
produced 
Early-ended 
Extremely 
reduced 
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Figure 1. Comparison of four fed-batch cultures with different levels of glucose starvation. Viable cell 
density, viability and integral of viable cells (IVC) vs. titer are presented in A, B and C, respectively. 
Glucose, lactate and ammonia concentrations in the course of cell culture are shown in D, E and F, 
respectively. The error bars represent the standard deviation calculated from duplicate experiments. The 
average specific production (+) or consumption (–) rate of glucose, lactate, glutamine, glutamate and 
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ammonia from day 9 to day 12 were calculated as:    
        
     
         
     
                
.          
     
  and          
     
 are the 
concentration of nutrients or metabolites in the cell culture on day 9 after feeding and on day 12 before 
feeding, respectively.         and          are IVC on day 9 and day 12, respectively. Slope 1: from day 2 
to day 5; slope 2: from day 5 to day 9. 
 
Figure 2. Intracellular nucleotide sugar analysis. Time course of concentration of intracellular nucleotide 
sugars (UDP-Glc, UDP-Gal, UDP-GlcNAc and UDP-GalNAc) from the cell cultures with different levels of 
glucose starvation were shown. Nucleotide sugar synthesis typically starts from degradation of glucose 
through glycolysis, in which glucose converts into glucose-6-phosphate and fructose-6 phosphate. 
Degradation of intracellular glucose generates Glucose-6-phosphate (Glc-6P), which is a critical substrate 
involved in glycolysis. Glc-6P can further become Fructose-6-pahospate (Fru-6P), which can enter into the 
TCA cycle for energy production, or together with glutamine supply biosynthesis of UDP-glucosamine 
(UDP-GlcNAc) and UDP-galactosamine (UDP-GalNAc.  Alternatively, Glc-6P can turn into Glucose-1-
phosphate (Glc-1P), which is responsible for generating UDP-glucose (UDP-Glc), UDP-galactose (UDP-
Gal).  In case of glucose starvation, lactate can be used as alternative carbon source to drive the TCA cycle. 
Once lactate is depleted, cells will mainly depend on using glutamine and other amino acids to support 
energy production and thus generate NH4
+
.  
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Nucleotide sugars (NSs) are metabolites that are required as substrates for the elongation of 
oligosaccharide chains during the process of glycosylation. Their concentrations in the cell have 
been demonstrated to be one of the major causes of alterations in mAb glycopatterns (Chee Furng 
Wong et al. 2005; Fan et al. 2014; Wong et al. 2010b).  It has been previously suggested that 
glucose depletion can reduce the biosynthesis of nucleotide sugars (Kochanowski et al. 2008). In 
accordance with this hypothesis, we observed reduced (LGS) or even fully depleted (HGS and SGS) 
intracellular concentrations of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and 
uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) when glucose availability was limited 
during the stationary phase of the fed-batch culture (Figure 2 – bottom). Counterintuitively though, 
considerable accumulation of uridine diphosphate glucose (UDP-Glc) and uridine diphosphate 
galactose (UDP-Gal) was observed after glucose starvation was induced at day 9 of culture (Figure 
2 – top). Although this finding may be seen as conflicting, a clear explanation can be found when 
considering the steps involved in NS biosynthesis and glutamine metabolism in CHO cells. Figure 2 
shows a simplified metabolic diagram for NS biosynthesis from glucose and glutamine (Gln) as 
primary substrates. There, we see that Fru-6P and Gln are combined to yield glucosamine 6-P 
(GlcN-6P), which eventually is converted to UDP-GlcNAc. Glutamine, in turn, has been widely 
reported to be consumed as an important carbon and energy source by CHO cells (Ahn and 
Antoniewicz 2013; Dean and Reddy 2013; Templeton et al. 2013; Young 2013). These authors have 
reported that considerable amounts of the Gln consumed during CHO cell culture is deamidated to 
yield ammonia and glutamate (Glu), the latter of which is then converted to TCA cycle 
intermediates such as oxaloacetate and -ketoglutarate (-KG). It is likely that under glucose 
starvation, glutamine and other amino acids uptake towards TCA cycle intermediates is increased in 
an attempt to sustain cellular energetic requirements, and that this increased glutaminolysis towards 
TCA cycle intermediates translates into a decreased flux of Gln towards GlcN-6P and eventual 
UDP-GlcNAc formation. Simultaneously, the flux of glucose that is not being converted to UDP-
GlcNAc due to lack of Gln availability can be funneled towards UDP-Glc and UDP-Gal formation, 
possibly generating the observed accumulation in the HGS and SGS cultures. This mechanism is 
further substantiated by the observed increase in both Glu and NH4
+
 concentration seen in Figures 1 
E and H, respectively, and a considerably higher Gln uptake rate in processes SGS and HGS. 
Alongside the possible metabolic effects described above, the consumption rate of the NSs for the 
glycosylation reactions must be considered. It is possible that UDP-Gal accumulates in the HGS 
and SGS cases because they present lower specific mAb productivity (Figure 1 C). If the drop in qp 
for these cases is higher than the drop in UDP-Gal biosynthesis, this NS would accumulate. 
Similarly, the NGS and LGS cases present accumulation of UDP-GlcNAc (Figure 2), higher Man 5 
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(Figure 3 A) and lower GlcNAc occupancy (Figure 4 A) after glucose starvation is induced. It is 
possible that UDP-GlcNAc accumulates in these cases because consumption of this NS towards 
glycosylation is lower. These results highlight the interplay between nucleotide sugar metabolism 
and recombinant protein productivity. 
To further elucidate whether changes in intracellular NS profiles are due to reduced biosynthesis 
associated with glucose starvation, changes in the mAb glycosylation distributions must be 
considered. The considerable changes in glycoform distribution observed between days 5 and 9 of 
culture reduce visibility of changes in glycosylation after glucose starvation is induced in Figures 3 
and 4. However, a positive correlation between the degree of glucose starvation and the maturation 
of glycans was observed in repeated experiments. 
 
 
 
Figure 3. Glycoprofiles of mAbs produced from the cell cultures with different levels of glucose starvation.  
(A) Mannose 5, (B) A1G0F, (C) G1F and (D) G2F 
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Figure 4. Average monosaccharide occupancy on glycans. (A) The percentage of GlcNAc occupancy (B) 
The percentage of galactose occupancy. The GlcNAc and Gal occupancy was calculated as reported in  (Fan 
et al. 2014). 
 
Table II. Fraction of total mAb secreted during each time interval and for all glucose limitation cases 
 
 
 
 
 
Table II shows the relative 
amount of mAb secreted 
during each time interval relative to the final mAb titer. There, we see that the fractions of secreted 
mAb change during the intervals depending on variations in specific productivity (qp), which are 
most likely a consequence of glucose availability for each case. Specifically, we see that a smaller 
fraction of the total mAb produced is being secreted by the HGS and SGS cases in the interval 
where glucose limitation was introduced (9 to 12d). When considering these changes in qp with 
respect to glucose availability, the reason why SGS yields a distribution with more highly processed 
glycoforms at day 12 is that during the starvation period, only 15.2% ± 0.5% of the total amount of 
mAb is produced. This lower fraction is diluted with the product that has been secreted up to that 
point in culture (84.8% ± 0.5%), and it is the dilution effect which leads to lower apparent decreases 
in mature glycoforms between days 9 and 12 (Figure 4). In contrast, a larger fraction of the total 
mAb is produced for the cases of less glucose starvation during the starvation period and thus, the 
dilution effect associated with changes in qp may mask the impact of cellular metabolism (via 
nucleotide sugar biosynthesis) on glycosylation.    
Time interval NGS LGS HGS SGS 
0 to 5d 8.7% ± 0.6% 11.9% ± 0.7% 17.1% ± 1.4% 19.2% ± 0.3% 
5 to 9d 31.9% ± 2.4% 46.7% ± 0.5% 60.3% ± 4.7% 65.6% ± 0.2% 
9 to 12d 34.5% ± 2.1% 35.5% ± 1.6% 22.6% ± 3.2% 15.2% ± 0.5% 
12 to 14d 24.9% ± 0.3% 5.9% ± 1.8% ------ ------ 
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Figure 5. Fraction of mAb glycoforms secreted before and during glucose limitation. The fraction of the 
Man5 (A), A1G0F (B), G0F (C), G1F (D) and G2F (E) glycoforms are presented for the intervals before (5 
to 9d) and after (9 to 12d) of glucose limitation. Each bar represents the different conditions of glucose 
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limitation during the day 9 to 12 period: NGS (   ), LGS (   ), HGS (   ) and SGS (   ). The values shown 
correspond to means for duplicate (n=2) cultures and statistical analysis was performed as described in the 
materials and methods. The criteria for significant differences are: * for p<0.05, ** for p<0.01 and *** for 
p<0.001. 
In order to account for the effect of qp on the glycan distributions after glucose limitation, the 
relative amount of each mAb glycoform produced (fi) during the interval was calculated based on a 
material balance for glycoform i (mAbi) over the starvation period: 
    
                     
           
 … Eq. 1 
Where qp is the mAb specific productivity and Xv is the average cell density over the time interval 
(from t1=9d to t2=12d for the starvation period). And considering that             
                         , we find a simpler expression for fi: 
    
                     
                         
… E . 2 
In equation 2, fi represents the mass fraction of mAb glycoform i produced relative to the total 
amount of mAb secreted during the time interval. Because Fc glycan variation accounts for very 
small changes in mAb molecular weight (<0.05%), fi was assumed to be a close approximation to 
the mole fraction of mAb glycoform i per total moles of mAb produced over the starvation interval. 
Figure 5 shows the fractions calculated with equation 2 for the interval before (day 5 to 9) and after 
(day 9 to 12) glucose starvation is induced for all degrees of glucose limitation (NGS, LGS, HGS 
and SGS). As expected, there are no statistical differences between the cases prior to glucose 
starvation (day 5 to 9) given that up to this point, all cultures were performed under similar 
conditions. However, statistically significant differences can be observed for Man5, G1F and G2F 
between the time intervals and among certain glucose starvation conditions during the 9 to 12d 
interval. 
Figure 5A shows that more Man5 is secreted during the 9 to 12d interval for all but the SGS culture. 
Within this interval, and depending on the different glucose starvation conditions, there is a 
decreasing trend where less Man5 is produced at higher glucose starvation. Specifically, the 
observed increases in Man5 secretion between both culture intervals are: NGS, 11.7% ± 0.8%; LGS, 
7.8% ± 2.2%; HGS, 6.3% ± 0.5%; SGS, no statistical difference (p<0.01 for all comparisons). 
These results are reflected in GlcNAc occupancy (Figure 5, bottom row), where this value was 
reduced by 10.5% ± 1.1% (NGS), 7.1% ± 1.3% (LGS) and 5.7% ± 0.7% (HGS) (p<0.01), and no 
statistically significant decrease was observed for the SGS culture. 
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When considering the intracellular UDP-GlcNAc concentrations presented in Figure 2, it is evident 
that lack of availability of this NS is not causing the increase in Man5 secretion for the NGS and 
LGS cultures. This is further substantiated by the small (4.4% ± 0.9%, p<0.05) decrease in G0F 
glycoform secretion after glucose starvation for NGS, and no statistically significant changes in 
A1G0F secretion (Figures 5 B and C). If UDP-GlcNAc availability were limiting, secretion of both 
these glycoforms would also be negatively impacted. Furthermore, the intracellular accumulation of 
UDP-GlcNAc, the increase in Man5 secretion, and the relative stability of G0F secretion imply that 
the rate limiting step is the reaction catalysed by the GnTI enzyme. The measured ranges for 
extracellular pH and ammonia concentration are below those that have been previously reported to 
impact the activity or Golgi localisation of GnTI (Borys et al. 1993; Gawlitzek et al. 2000; Rivinoja 
et al. 2009). The remaining possible cause for increased Man5 secretion in the least glucose-
deprived cultures is the abundance of GnTI relative to specific mAb productivity. When considering 
this is the limitation, intracellular accumulation of UDP-GlcNAc is explained: a low GnTI to qp 
ratio in NGS and LGS reduces the rate of GlcNAc transfer onto Man5, and because less UDP-
GlcNAc is being consumed for this reaction, this NS accumulates within the cells. 
In contrast to GlcNAc occupancy, production of galactosylated glycoforms (G1F and G2F, Figures 
5 D and E, respectively) increases with higher glucose starvation. No statistical differences were 
observed for G1F secretion before and after starvation for the HGS and SGS cultures, but a 
decrease of 1.5% ± 0.3% was observed for NGS and LGS (p<0.05). In general, more G2F 
glycoform was produced during the starvation interval. However, a more pronounced increase in 
G2F secretion before and after starvation was observed for the HGS and SGS cultures (P<0.001). 
The above results are also clearly reflected in Gal occupancy (Figure 5, bottom row). Specifically, 
galactose occupancy was not affected for the HGS and SGS cases, but was observed to decrease for 
NGS and LGS (1.0% ± 0.2% for both cases, p<0.05). 
When comparing galactose occupancy with intracellular UDP-Gal availability (Figure 2), we see a 
positive correlation. Higher intracellular UDP-Gal availability occurs for the most glucose starved 
cultures (HGS and SGS). In turn, these cultures present higher galactose occupancy during the 
starvation interval. The mechanisms underlying the interplay between intracellular UDP-Gal 
concentration, galactose occupancy and specific mAb productivity are consistent with the 
arguments put forth for GlcNAc. UDP-Gal accumulation in HGS and SGS is unlikely due to excess 
biosynthesis because these cultures were performed under considerable glucose limitation. 
Considering this, the most likely cause for intracellular UDP-Gal accumulation is that it is being 
consumed at a lower rate due to the low specific mAb productivity observed under these glucose 
starvation conditions (HGS and SGS). In turn, a lower qp also implies higher residence time within 
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the Golgi apparatus which would allow for further processing of the mAb-bound glycans, leading to 
higher galactose occupancy. In summary, higher galactosylation occurs in the HGS and SGS 
cultures because the amount of galactosylation machinery (GalT and UDP-Gal transporter) is in 
excess relative to the specific mAb productivity. 
Regarding charge heterogeneity of the mAbs by CIE analysis, slightly higher amount of basic 
variants (basic 1 and 2 isoforms) as well as slightly lower amount of acidic variants was associated 
with increasing degree of glucose starvation (Figure 6). This confirmed our findings in the 
glycoprofile in view of the fact that the mAbs with Man5 may contribute to basic variant (Yan et al. 
2009). It is also likely that the amount of deamidated (contributing to the acidic variants) and 
methione-oxidated or succinimide-contained mAb (contributing to the basic variants), which could 
be altered under different degree of glucose starvation (Chumsae et al. 2007; Harris et al. 2001; 
Perkins et al. 2000; Zhang et al. 2011).  
 
Figure 6. Charge heterogeneity of mAbs produced from the cell cultures with different levels of glucose 
starvation.  
It is also worth mentioning that no peak representing non-glycosylated mAbs (typically appeared as 
a very basic distinct peak (Gaza-Bulseco et al. 2008) separated from the main peak with heterogenic 
shoulders) was detected in samples from any of the four processes using CIE analysis. The result 
was also confirmed by intact mass analysis of the mAbs using LC-MS (data not shown). This 
indicated that no change in glycosylation site occupancy due to glucose starvation was observed in 
this study. 
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Previous results showed that glucose starvation can cause an increasing amount of non-glycosylated 
mAbs and less matured glycoforms (Liu et al. 2014). However, our findings concerning the effect 
of glucose starvation on both microheterogeneity and macroheterogeneity of the mAb glycosylation 
are contradictive to that. A possible reason could be that glucose starvation in this study occurred in 
the stationary phase of fed-batch culture compared to the previous study, in which glucose 
starvation occurred in the beginning of the batch culture. Hence, the physiological status of the cells 
and the interplay between nucleotide sugar availability and qp are not comparable in these two 
cases, which in turn lead to different impact on mAb glycosylation. Furthermore, we have found 
that intracellular availability of nucleotide sugars may be dictated by the rate of consumption for 
glycosylation and not being themselves the limiting substrates for glycosylation. Although this may 
be a cell line or process-specific observation, we have shown that integrating nucleotide sugar 
availability with additional cell culture data is crucial for elucidating the metabolic mechanisms 
underlying mAb glycosylation during cell culture. 
6.3.2. Effect of culture duration 
Appropriate harvest criteria need to be selected for mAb manufacture. Here, we analyzed the fed-
batch culture at different time points and try to understand the balance between titer and quality of 
the mAbs in relation to the culture duration.  
As shown in Figure 1 C, the specific productivity of mAbs was lower in early growth phase (slope 1, 
day 2 to 5) comparing to that in late growth phase and early stationary phase (slope 2, day 5 to 9), 
which indicates there is an increase in qp after temperature shift. 
In the process with no glucose starvation (NGS), we found that all measured NSs accumulated as 
cultivation duration increased, which implies the biosynthesis rates were generally higher than the 
consumption rates of these nucleotide sugars along the culture process. Interestingly, UDP-GlcNAc 
and UDP-GalNAc accumulation was considerably increased at the end of the fed-batch process 
(from day 12 to 14). This can be attributed to increased UDP-GlcNAc biosynthesis, given a 
decrease in NH4
+
 accumulation in the culture after day 9 (Figure 1 H). 
The variations in charge heterogeneity along the cell culture (Figure 6) can be attributed to 
combinations of many different factors, including increased deamidation, oxidation and less-
processed glycosylation of the mAbs. Therefore, the trend of such changes may be quite different 
from case to case. On the other hand, charge heterogeneity of mAbs can therefore be used as a 
general indicator to access the quality of mAbs.  
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With regards to glycosylation (Figure 3 and Figure 4), it has been demonstrated by a trend of 
overall increases in Man5 and A1G0F, and decreases in G1F, G2F, and GlcNac and galactose 
occupancy along cultivation. This finding is in accordance with the apparent accumulation of UDP-
GlcNAc and UDP-Gal during the cell culture as well (Figure 2). 
More specifically, the most dramatic changes in glycoform distribution observed in this study occur 
between days 5 and 9 (Figure 3), where Man5 glycoform abundance increases by 11.6% ± 0.3% 
(from 2.7% ± 0.2% to 14.4% ± 0.2%) and the G1F glycoform decreases by 11.9% ± 0.7% (from 
26.6% ± 0.7% to 14.7% ± 0.1%). The similarity between the changes in Man5 and G1F abundance 
is striking and is likely related: higher Man5 production leaves less glycoprotein substrate available 
for galactosylation during later stages of the glycosylation process within the Golgi apparatus. It is 
therefore possible that the drop in galactosylation is a direct consequence of high Man5 secretion.  
A similar correlation (glycans become less processed with extended culture duration) has also been 
reported in other studies (Bibila and Robinson 1995; Hooker et al. 1995; Pacis et al. 2011; 
Robinson et al. 1994; Shi and Goudar 2014), which indicate that this could be a general 
phenomenon. Three major hypotheses have been proposed explaining such a phenomenon: 1) A 
bottleneck in the availability of nucleotide sugar substrates with respect to culture duration may 
exist (Hooker et al. 1995). However, this possibility can be ruled out in the NGS process, as the 
nucleotide sugar substrates such as UDP-GlcNAc and UDP-Gal were accumulated in the cells over 
time (Figure 2). In addition, no considerable drop in G0F glycoform was observed along the cell 
culture (data not shown), indicating that UDP-GlcNAc availability is not limiting. 2) Cell death and 
lysis, may elevate the activity of extracellular glycosidase, especially sialidase in the culture, and 
thus increase the glycan degradation (Chee Furng Wong et al. 2005).  However, it has also been 
demonstrated that CHO-derived glycosidases including β-galactosidase, β-hexosaminidase may be 
less likely to contribute to the lower GlcNAc and Gal occupancy, since they exhibit very low 
activity at typical culture pH (Gramer and Goochee 1993). 3) Reduced expression or activity of 
Golgi-associated mannosidase and glycosyltransferases during the course of culture (Robinson et al. 
1994) can lead to high mannose and low galactosylation. However, as reported previously, the 
changes in expression of GlcNAc transferase I (GnT1) during the course of a cell culture is cell 
line-dependent and do not show any general trend of decline (Fan et al. 2014; Pacis et al. 2011). 
Additionally, no apparent down-regulation was observed in the expressions of GlcNAc transferase 
II (GnTII) and various galactose transferases (GalT) along with increased culture duration (Wong et 
al. 2010a). Although the activities of these enzymes may be inhibited by temperature shift or by 
changed pH inside Golgi apparatus, especially when ammonia accumulation increased in the culture, 
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the reported effective concentration of ammonia on glyco-alterations was above 10mM (Borys et al. 
1994; Chen and Harcum 2005; Gawlitzek et al. 2000). In our case, ammonia accumulation in the 
cell culture without glucose starvation is less than 6mM, which is well below the effective 
concentration. Therefore, reduced activities of glycosylation-associated Golgi resident proteins in 
the course of cell culture due to ammonia accumulation may not be the right explanation for the 
culture duration-dependent glyco-alterations. Temperature shift may contribute to the decreases 
before and after day 5 in glycan maturation as a result of reduced activities of these enzymes. 
Additionally, Figure 1 C also shows that the qp increases after the temperature shift on day 5 (slope 
1 vs. slope 2). Therefore, it is possible that this increase in qp causes the decrease in glycoform 
complexity between 5 and 9 days of culture. If the abundance of GnTI relative to the qp goes below 
a certain level, lower GlcNAc occupancy will be achieved. These results point to the importance of 
considering the capability of glycosylation machinery available with respect to specific productivity. 
However, it cannot fully explain the continuous decrease in glycan maturation during the period 
after the temperature shift. As all three major hypotheses do not completely fit the reported system-
level data, further investigations are needed in understanding the root cause of this type of 
glycosylation change. 
6.3.3. Comparative proteomics analysis between growth phase and stationary phase in fed-batch 
In order to gain insight into the fundamental differences in the cell culture from growth phase to 
stationary phase, in-depth analysis of proteome changes in cells from the two phases in the NGS 
process was performed. 
In total across all samples, 5113 proteins were identified with FDR<1% in the proteomics data 
(Table S1), in which 4647 proteins were processed using gene set enrichment analysis (GSEA, 
Table S3). 3294 proteins were enriched into 228 and 334 gene sets using functional database and 
gene ontology database, respectively (Table S4 and S6). Enrichment maps illustrating GSEA results 
were built. The enriched gene sets containing genes with statistically significant changes in protein 
level between the growth phase and stationary phase were shown in Figure 7. In growth phase, the 
genes in the gene sets with transcription, cell cycle and nucleotide metabolism related activity were 
generally expressed at higher level, which is consistent with the rapid cell growth during this phase. 
On the other hand, the genes in the gene sets regarding glucose, lipid, and nucleotide sugar 
metabolism, environmental sensing and signal transduction, protein trafficking and secretion, 
glycosylation and apoptosis related activity were up-regulated in the stationary phase. Specifically, 
increasing environmental sensing and signal transduction related activity in stationary phase 
involved a number of gene sets found in both databases. This implies that cells may be more 
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sensitive to and tightly regulated upon environmental changes, for example media and process 
conditions in the stationary phase than in growth phase. Another interesting point we found is that 
protein trafficking and secretion were more active in the stationary phase with regard to in the 
growth phase, as a large set of genes involved in this activity were up-regulated. Therefore, we 
suggest that the cellular machinery in relation to protein secretion was more active for cells in 
stationary phase than in growth phase. In contrast to that, genes in the gene sets regarding 
glycosylation related activity are very few, although they were shown to be up-regulated (Figure 7).   
Taking one step more, we further specifically analyzed the proteome involved in the secretion 
machinery (Table S9), nucleotide sugar synthesis pathway (Table S10) and biosynthesis pathway of 
N-glycans (Table S11).  
 
Figure 7. Enrichment map based on gene set enrichment analysis of comparative proteomics. The analysis 
has been done using (A) functional database and (B) gene ontology database, respectively.  All enriched 
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gene sets are represented as dots. The size of the dot indicates the size of the gene set. Red dot signifies the 
genes in that gene set is generally up-regulated in the growth phase (on day 2) of the fed-batch culture, 
whereas blue dot stands for general up-regulation of the genes in the stationary phase (on day 9). Overlapped 
genes between the two gene sets were shown as green line. The thickness of the green light represents the 
size of the overlapped genes. Further clustering of the enriched gene sets based on their descriptions was 
indicated using light blue circles.  
The relative activation of secretion machinery during the stationary phase has been demonstrated in 
(Table S9). We found that 12 proteins were up-regulated in stationary phase within our cut-off 
criteria. Out of the 12 proteins three (XP_003514816, XP_003499981 and XP_003512468) are 
directly related to protein transport in the cell and three (XP_003504664, XP_003501071 and 
XP_003507839) are responsible for protein folding. In contrast, only seven proteins were up-
regulated in growth phase within the cut-off criteria. Interestingly, three of them were heat-shock 
proteins (HSP), which may reflect the effect of temperature shift during the culture. It is also worth 
to mention that many of the HSPs are glycosylated (Baycin-Hizal et al. 2012), and the glycosylation 
of them might compete with recombinant protein glycosylation. 
In the nucleotide sugar synthesis pathway, Proteins XP_003497644, NP_001233687 and 
XP_003515993 that are responsible for UDP-Glc and UDP-Gal biosynthesis were slightly up-
regulated in stationary phase (Table S10). The expressions of NP_001233638 and XP_003514714 
that can direct UDP-GlcNAc to UDP-GalNAc and N-Acetyl-D-mannosamine (ManNAc), 
respectively, were higher in stationary phase. These results are in agreement with the findings above 
(Figure 7) that genes involved in nucleotide sugar metabolism were generally up-regulated in 
stationary phase. 
Regarding the biosynthesis pathway of N-glycans (Table S11), three proteins (XP_003500143, 
XP_003500900, XP_003508783) that are responsible for initiation of N-glycosylation in the ER 
were slightly up-regulated during the stationary phase. Very interestingly, the expression of only 
two protein α-mannosidase II (XP_003499415) and GnT1 (NP_001230909) involved in glycan 
maturation in Golgi apparatus were slightly higher during the stationary phase. 
Taken together, the essential causal link between producing the less processed glycans with 
increasing culture duration could be narrowed down to the following two possibilities: First and 
most likely, it can be attributed to the overall capabilities of protein secretion machinery from 
growth phase to stationary phase in the cells gradually exceeding the capability of protein 
glycosylation machinery that is specifically responsible for glycan maturation. Secondly, it is also 
possible that the activities of enzymes that raise GlcNac and Gal occupancy may be reduced due to 
certain environmental change and/or physiological response (e.g. temperature shift and/or pH 
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gradient across the network of ER and Golgi apparatus) of the cells with the cultivation duration 
increased. 
Further leading-edge analysis (LEA) was performed using the output from GSEA. Based on the 
functional database and the gene ontology database, we identified 655 leading edge genes in 172 
gene sets and 568 leading edge genes in 144 gene sets, respectively (Table S4-S7). The top 10 up 
and down-regulated genes and enriched gene sets from LEA were shown from Table III to Table VI. 
The majority of the top up-regulated genes on day 2 are related to cell growth and cell cycle 
progression and are located in nucleus (Table IV and VI), including TOP2A, KPNA2, KIF22, 
UBE2C, DNMT1, LIG1, KIF4A, and MCM2, 3 and 5 (Table III and V).  
 
Table III. Up and down regulated proteins on day 2 comparing to day 9 gene ontology database using 
leading-edge analysis. H: Human; M: Mouse; E: Eukaryote; C: CHO; R: Rat. 
#
overlapped genes in Table V.  
CHO RefSeq Gene Symbol Log2ratio 
Cells 
studied 
Function Reference 
Up-regulated 
   
  
NP_001233667 TOP2A 1.82 H Transcription, DNA replication (Belluti et al. 2013) 
XP_003501907 KPNA2 # 1.63 H Cell proliferation, cell cycle (Huang et al. 2013) 
XP_003510169 KIF22 # 1.61 H Cell mitosis, cell cycle (Yu et al. 2014) 
XP_003504632 UBE2C # 1.55 H Ubiquitylation, cell cycle (Mocciaro and Rape 2012) 
XP_003499794 DNMT1 1.53 H  DNA replication (Shimamura and Ishikawa 2008) 
XP_003500203 LIG1 # 1.39 H DNA repair, DNA replication (Ferrari et al. 2003) 
XP_003504365 HMGB2 1.36 H DNA repair (Nagaki et al. 1998) 
XP_003499302 KIF1A 1.33 M  Axonal transport (Okada et al. 1995) 
XP_003509164 KIF4A # 1.32 H Cell mitosis (Mazumdar et al. 2004) 
XP_003500277 MCM2 # 1.25 E DNA replication (Bell and Dutta 2002) 
Down-regulated 
   
  
XP_003510318 LGALS1 -1.22 H, M Apoptosis (Scott and Weinberg 2002) 
XP_003510519 ANXA1 # -1.27 H, C Apoptosis; protein productivity (Meleady et al. 2011; Wu et al. 2000) 
XP_003500109 LGALS3 -1.30 H Apoptosis (Nakahara et al. 2005) 
XP_003515030 COL5A2 # -1.44 R Extracellular matrix regulation  (Liu et al. 2010) 
XP_003500579 PLTP # -1.51 H, C Lipid transfer (Vuletic et al. 2009) 
XP_003504285 COL7A1 # -1.63 R Extracellular matrix regulation (Liu et al. 2010) 
XP_003496178 MMP12 -1.69 C Extracellular matrix regulation (Sandberg et al. 2006) 
XP_003515352 FCGRT -1.71 H IgG binding and protection (Story et al. 1994) 
XP_003514816 VAMP3 # -1.74 H Protein secretion (Kean et al. 2009) 
XP_003503110 PLG # -1.75 C Extracellular matrix regulation (Rossignol et al. 2004) 
 
Table IV. Up and down regulated gene sets on day 2 comparing to day 9 using gene ontology databases. 
Size: numbers of genes consist in enriched gene set; NES: normalized enrichment sore of enriched gene set; 
NoM p: normalized p value of enriched gene set; FDR q: false positive rate of enriched gene set.  
GENE SET SIZE NES NoM p FDR q 
DNA Binding 76 2.661 0 0 
Nucleus 283 2.586 0 0 
Nuclear Part 122 2.557 0 0 
RNA Processing 47 2.494 0 0 
Cell Cycle 59 2.391 0 0 
Chromosome 29 2.388 0 0 
Nuclear Lumen 71 2.383 0 0 
Nucleobase/nucleoside/nucleotide and Nucleic Acid 227 2.376 0 0 
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Metabolic Process 
Nucleoplasm 48 2.299 0 0 
RNA Metabolic Process 148 2.29 0 0 
Endopeptidase Activity 24 -1.959 0 0.006 
Tissue Development 15 -1.961 0 0.006 
Membrane 262 -1.963 0 0.008 
Extracellular Region Part 29 -1.963 0 0.007 
Plasma Membrane Part 100 -2.005 0 0.006 
Plasma Membrane 139 -2.066 0 0.003 
Cellular Lipid Metabolic Process 44 -2.078 0 0.003 
Extracellular Region 45 -2.111 0 0.002 
Receptor Binding 42 -2.126 0 0.002 
Lipid Metabolic Process 57 -2.277 0 0 
 
Table V. Up and down regulated proteins on day 2 comparing to day 9 found in functional database using 
leading-edge analysis. H: Human; M: Mouse; E: Eukaryote; C: CHO; 
#
overlapped genes in Table III. 
CHO RefSeq Gene Symbol Log2ratio 
Cells 
studied 
Function Reference 
Up-regulated 
   
  
XP_003501907 KPNA2 # 
Same as in table III 
XP_003510169 KIF22 # 
XP_003504632 UBE2C # 
XP_003500203 LIG1 # 
XP_003509164 KIF4A # 
XP_003500277 MCM2 # 
XP_003509175 MCM3 1.25 E DNA replication (Bell and Dutta 2002) 
XP_003506293 DUT 1.25 H DNA replication (McIntosh et al. 1992) 
XP_003498829 EIF5 1.15 R Translation initiation (Si et al. 1996) 
XP_003512004 MCM5 1.14 E DNA replication (Bell and Dutta 2002) 
Down-regulated 
   
  
XP_003498026 CTSB -1.22 H Apoptosis, (Bruneel et al. 2005) 
XP_003502412 IDUA -1.22 H Glycosaminoglycan  metabolism (Bie et al. 2013) 
XP_003515581 ABCA4 -1.22 M Phospholipid translocation (Weng et al. 1999) 
NP_001233729 NEU1 -1.26 C Glycosylation (Chee Furng Wong et al. 2005) 
XP_003510519 ANXA1 # 
Same as in table III 
XP_003515030 COL5A2 # 
XP_003500579 PLTP # 
XP_003504285 COL7A1 # 
XP_003514816 VAMP3 # 
XP_003503110 PLG # 
 
Table VI. Up and down regulated gene sets on day 2 comparing to day 9 found in functional database. Size: 
numbers of genes consist in enriched gene set; NES: normalized enrichment sore of enriched gene set; NoM 
p: normalized p value of enriched gene set; FDR q: false positive rate of enriched gene set.  
GENE SET SIZE NES NoM p FDR q 
Reactome mRNA processing 50 2.704 0 0 
Reactome processing of capped intron containing pre-mRNA 44 2.643 0 0 
Reactome RNA splicing 32 2.55 0 0 
KEGG spliceosome 43 2.539 0 0 
KEGG cell cycle 30 2.459 0 0 
Reactome transcription 41 2.399 0 0 
Reactome cell cycle mitotic 81 2.312 0 0 
Reactome RNA Polymerase II Transcription 31 2.295 0 0 
Reactome DNA repair 25 2.272 0 0 
Reactome Transcription-coupled NER (TC-NER) 15 2.255 0 0 
Reactome platelet activation signaling and aggregation 49 -1.965 0 0.007 
Reactome phospholipid metabolism 38 -1.989 0 0.006 
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KEGG fatty acid metabolism 17 -1.999 0 0.006 
KEGG PPAR signaling pathway 17 -2.005 0 0.006 
KEGG ECM receptor interaction 15 -2.109 0 0.003 
Reactome metabolism of lipids and lipoproteins 104 -2.126 0 0.003 
Reactome sphingolipid metabolism 16 -2.137 0 0.003 
KEGG focal adhesion 50 -2.237 0 0 
Reactome extracellular matrix organization 17 -2.238 0 0.001 
KEGG lysosome 38 -2.603 0 0 
 
Taking a few examples, TOP2A encoding a nuclear DNA topoisomerase, which regulates topologic 
states of DNA during transcription and replication (Belluti et al. 2013). KPNA2 nuclear transport of 
proteins have recently been confirm to promote cell proliferation via c-Myc and cyclin-dependent 
kinase CDK regulation (Huang et al. 2013). KIF22 (a molecular motor) and UBE2C (a cell cycle 
regulators) have been reported to be involved in cell division (Mocciaro and Rape 2012; Yu et al. 
2014). Additionally, MCM2, 3 and 5 are implicated in the formation of replication forks during 
DNA replication (Bell and Dutta 2002). These findings are in agreement with the results from the 
enrichment maps in figure 7 and the nature of the cells in growth phase.  
On the other hand, the top up-regulated genes on day 9 are located at membrane and extracellular 
region and are mainly involved in extracellular matrix regulation, cell proliferation and apoptosis, 
protein secretions, lipid transport and glycosylation (Table IV and VI).  
COL5A2 and COL7A1 regulate the expression of collagens may cause alterations in extracellular 
matrix (Liu et al. 2010). Previous studies also show that change in the expression of COL5A2 was 
observed in sodium butyrate treated CHO cells based on the mRNA-seq data (Birzele et al. 2010). 
Additionally, PLG were also shown to participant in degradation of extracellular matrix (Rossignol 
et al. 2004). MMP12 functioning in extracellular matrix degradation, were found to be released 
from CHO cells producing recombinant factor VIII during the production phase (Sandberg et al. 
2006). VAMP3 has been postulated to be a component of early/recycling endosomal v-SNARE 
responsible for protein trafficking and secretion and may contribute to extracellular matrix 
degradation (Kean et al. 2009). Taking all these into consideration, the change in extracellular 
matrix may be a physiological characteristic of cells in stationary phase.  
Highly regulated apoptosis seems to be another molecular feature during the stationary phase. 
ANXA1 belongs to annexin protein family, can bind phospholipid in a calcium-dependent manner, 
which was demonstrated to be essential for cell proliferation and apoptosis (McKanna 1995; Wu et 
al. 2000). It was also suggested to be in association with sustaining high productivity of 
recombinant protein over the duration of a CHO fed-batch culture (Meleady et al. 2011). LGALS1 
and LGALS3 code for Galectin-1 and Galectin-3, respectively. Galectins are types of lectins that 
bind β-galactosides. Galectin-1 has been demonstrated to play different roles in cell survival and 
proliferation as a mitogen, a cell proliferation inhibitor, or a cell apoptosis promoter (Scott and 
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Weinberg 2002). Similarly, Galectin-3 was also found to have a biological function in regulating 
cell proliferation and apoptosis (Nakahara et al. 2005).  
Also notably, the expression of sialidase-1 (encoded by NEU1) that cleaves terminal sialic acid 
residues from glycans is up-regulated in the stationary phase. This is the likely basis of the report 
that decreased sialylation of recombinant proteins correlates with the increased culture duration 
(Chee Furng Wong et al. 2005). 
6.4. Conclusion 
Using systems biology-based approaches, we have shown here the effects of glucose starvation and 
culture duration on fed-batch CHO cell culture producing monoclonal antibody and the underlying 
reasons that cause such effects. Glucose starvation at the stationary phase of the fed-batch culture 
exhibited a negative impact on growth, viability, and specific productivity of the cells. It was also 
shown that the changes of glycoforms (increased GlcNAc and Gal occupancy) in regard to 
increased degree of glucose starvation are as a result of interplay between the dilution effect 
associated with change in qp and the changed nucleotide sugar metabolism. On the other hand, the 
effect of culture duration on the glycopatterns is dramatic. In general, longer culture duration leads 
to a higher abundance of less processed glycan structures. Especially between samples from growth 
phase and stationary phase, the extent of such effect is immense, which was thought to be correlated 
with the fundamental physiological difference between cells in the two phases. For that reason, we 
took one step further to examine the differences between proteome levels in these two phases. We 
found that the expression of proteins regarding cell cycle progression and cell divisions are 
generally up-regulated in growth phase. On the other hand, expression of proteins that is responsible 
for regulating cellular metabolism, extracellular matrix, apoptosis, protein secretion and 
glycosylation is generally higher in stationary phase. Very importantly, a large repertoire of proteins 
concerning secretion machinery was generally up-regulated in the stationary phase, whereas only 
two proteins (α-mannosidase II and GnT1) regarding glycan maturation in Golgi apparatus were 
found to be slightly up-regulated. In this way, we gained deeper insight into the culture behavior 
and recombinant protein production on the basis of the molecular features of the cells.  From the 
process control perspective, this proteome information could help discover and apply knowledge of 
cellular functions in response to changes in process conditions, in order to explore possiblities of 
producing recombinant product with optimal productivity and quatlity.   
We have not excluded the possibility of cell line specific effects on our data, and ideally different 
cell lines should be further investigated. However, the systems biology-based analysis constitutes a 
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powerful tool for studying the physiological profiles of cells under different culture conditions and 
linking that with the quantity and quality of the recombinant product. 
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Abstract 
In this study, metabolic engineering have been carried out in order to develop cell lines that have 
better capacity of producing monoclonal antibodies (mAbs) with more matured glycans. IgG-
producing cell lines with stable overexpression of α-1,3-mannosyl-glycoprotein 2-β-N-
acetylglucosaminyltransferase (GnTI) or UDP-GlcNAc transporter was generated. To gain better 
insight of the interplays among GnTI or UDP-GlcNAc expression, mAb productivity, nucleotide 
sugar metabolism, N-glycosylation quality during fed-batch culture, selected cell lines are assessed 
and compared.  
We found that overexpression of GnTI can be use as a strategy to generate cell lines that produce 
less Man5 and higher GlcNAc occupancy of mAb N-glycans. On the other hand, overexpression of 
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UDP-GlcNAc transporter seems to have no apparent effect on increasing GlcNAc occupancy in the 
cell lines tested. Moreover, clone specific effect in association with specific productivity of mAb 
can also influence the maturation of glycans. In general, cell lines with lower specific productivity 
may have the tendency to produce mAb with higher level of GlcNAc and Gal occupancy. 
7.1. Introduction 
Recombinant therapeutic protein glycosylation plays a critical role in changing several product-
associated attributes, including bioactivity, stability, immunogenicity and etc.  (Arnold et al. 2007; 
Costa et al. 2013). In the biopharmaceutical industry, an absolute glycosylation requirement is one 
of the main reasons that mammalian cell culture systems, in particular, Chinese hamster ovary 
(CHO) cells were used for the manufacturing process. Despite the human-like glycosylation 
patterns of CHO-derived recombinant proteins, controlling and modulating recombinant protein 
glycosylation in CHO cells towards more desired patterns remains one of the major challenges 
during cell line and process development.  
CHO cell engineering has been demonstrated to be able to, for example shift metabolic pathways 
for more efficient energy utilization (Jeon et al. 2011; Kim and Lee 2007a; Kim and Lee 2007b; 
Park et al. 2000), enhance productivity of the cells (Dreesen and Fussenegger 2011; Meleady et al. 
2012; Tigges and Fussenegger 2006), and improve longevity of the culture (Banmeyer et al. 2004; 
Druz et al. 2013; Figueroa et al. 2007; Mastrangelo et al. 2000). More importantly, CHO cell 
engineering has been extensively used in optimizing quality attributes of the product, particularly 
glycosylation (Chapter 2) (Le Fourn et al. 2014). For example, many studies have been focused on 
improving ADCC activity of IgG by engineering CHO cells using two different strategies, namely 
producing bisecting GlcNAc (Davies et al. 2001; Umana et al. 1999) or afucosylated glycan 
structure (Imai-Nishiya et al. 2007; Kanda et al. 2007; Mori et al. 2004; Yamane-Ohnuki et al. 
2004). In the light of recent advance in CHO genomics (Xu et al. 2011), new exploration and 
innovation in CHO cell engineering, especially in glycosylation engineering become more feasible 
(Maszczak-Seneczko et al. 2011; North et al. 2010; Sealover et al. 2013). 
One of the key objectives of recent cell line and process development is to increase productivity of 
a cell line, so that higher yield of product can be achieved. However, as a cost of that, reduced 
maturation of glycans, for example increased Man5, decreased GlcNAc and Gal occupancy of 
glycans are always associated (Chapter 6). That is always due to bottlenecks in glycosylation-
associated Golgi resident protein availability relative to recombinant protein productivity of the 
cells (Fan et al. 2014). It has been reported that elevated high mannose glycans and reduced 
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GlcNAc and Gal occupancy of glycans may increase immunogenicity and influence the serum half-
life of mAbs (Shi and Goudar 2014). Therefore, during the cell line and process development, 
strategies of improving the maturation of glycans need to be addressed as well. 
In this study, we use metabolic engineering approaches to develop cell lines that may have better 
capacity of producing mAbs with more matured glycans. α-1,3-mannosyl-glycoprotein 2-β-N-
acetylglucosaminyltransferase (GnTI, which is the enzyme in Golgi that is responsible of 
transferring a GlcNAc residue onto Man5 glycan) or UDP-GlcNAc transporter (the enzyme that can 
transport UDP-GlcNAc from cytosol into Golgi apparatus) was overexpressed in two parental mAb-
producing cell lines. Fed-batch culture performance, mAb production, intracellular nucleotide sugar 
availability and glycoprofiles of parental and engineered cell lines are evaluated and compared. Our 
results demonstrate potential strategies of generating cell lines that can produce less Man5 and 
higher GlcNAc occupancy of glycans and provide a holistic understanding of interrelations of cell 
growth, mAb production, glycosylation-associated enzymes, nucleotide sugar metabolism and 
glycosylation in fed-batch CHO cell culture. 
7.2. Materials and Methods 
7.2.1. High throughput USER Cloning  
Plasmids used in this study were modified from Selexis mammalian expression SLXplasmid_0191 
(containing puromycin-resistance gene) and SLXplasmid_0192 (containing hygromycin-resistance 
gene). The GFP sequence of both original plasmids was replaced by a USER cassette to create 
USER cloning-compatible plasmids (Figure S1). A USER cloning-based mammalian expression 
vector assembly method (Lund et al. 2014) was used for constructing the plasmids used in this 
study (Figure 1). DNA building blocks were amplified by PCR using proofreading polymerase 
PfuX7 (Norholm 2010). Primers used in this study were listed in Table S1. PCR templates in this 
study are all commercially available (Table S2). The cDNA sequences of Chinese hamster GnTI 
(NM_001243980) and UDP-GlcNAc transporter (NM_001246818) were obtained from gene bank. 
DNA fragment of C-terminal HA-tagged GnTI and N-terminal FLAG-tagged UDP-GlcNAc 
transporter were synthesis and cloned in to pUC57 by GenScript. Four plasmids (p1, p2, p3 and p4) 
have been generated by USER assembly. The sequences of PCR amplified regions in all plasmids 
have been confirmed by sequencing.  
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7.2.2. Transfection and stable cell line generation 
Cell lines A and B, which were used in this study, are two Symphogen in-house IgG1-producing 
CHO DG44 suspension cell lines. Cells were thawed and maintained in proprietary serum-free basal 
medium at 37˚C, 5% CO2, 200 rpm. Two hours prior to transfection, cells were transferred to 
transfection medium, which consists of freestyle CHO expression medium (Gibco) supplemented 
with 8 mM L-glutamine (Gibco). Transfection mix for each transfection was prepared, which 
contains 10 µg of plasmid, 500 µl Opti-MeM
®
 reduced serum media (Invitrogen, Life Technologies) 
and 40 µl of FuGENE HD reagent (Roche). Upon transfection, the transfection mix was incubated 
with 5x10
6
 cells resuspended in 10 ml transfection medium in 50 ml TPP® TubeSpin bioreactor 
tube (Sigma-Aldrich) for two hours. After transfection, cells were cultivated in proprietary cloning 
medium. Two days after transfection, 5 µg/ml puromycin (Invitrogen, Life Technologies) or 250 
µg/ml hygromycin (Invitrogen, Life Technologies) selection was applied to the cells accordingly. 
Cells were continued to cultivate under the selection pressure for three weeks. Stable single cell 
clones were generated using FACS Aria™ II flow cytometry (BD biosciences) and were expanded 
in the proprietary cloning medium. Further clone selection was carried out based on the intensity of 
corresponding florescence signals (eGFP or mCherry) of the cells using Cellavista imaging system 
(SynenTec). Cells that are expected to have stable and relative higher overexpression of GnTI 
(strong mCherry signal) or UDP-GlcNAc transporter (strong eGFP signal) were selected and 
maintained in the proprietary basal medium for further analysis. 
7.2.3. Confirmation of the overexpression  
The expression level of GnTI or UDP-GlcNAc transporter in the parental (A and B) and engineered 
(A-M18, A-E15, B-M4, B-M7 and B-E15) cell lines was determined by Western blot analysis as 
described in (Fan et al. 2014). Intracellular immunostaining was carried out to confirm the 
subcellular localization of the overexpressed enzymes. Cells expressed HA-tagged GnTI and 
FLAG-tagged UDP-GlcNAc transporter were washed with PBS (Invitrogen, Life Technologies) 
and fixed with 4 % paraformaldehyde (PFA; Thermo Scientific) for 20 min. The cells were 
subsequently permeabilized with 0.2 % Triton X-100 for 3 min and blocked with 1% BAS in PBS 
for 15 min. The cells were then incubated with rabbit anti-GM130 Golgi protein antibody (1:135, 
Abcam) and mouse anti-HA (1:160, Sigma-Aldrich) or anti-FLAG (1:160, Sigma-Aldrich) antibody 
for 1h and washed three times with 1% BAS in PBS. After 1 h incubation with goat anti-rabbit 
Alexa Fluro 647-conjugated antibody (for the detection of Golgi marker antibody; 1:100; Invitrogen, 
Life Technologies) and goat anti-mouse Alexa Fluor 488 (for the detection of HA tag; 1:100; 
Invitrogen, Life Technologies) or 546-conjugated antibody (for the detection of FLAG tag; 1:100; 
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Invitrogen, Life Technologies), the cell were stained with 1:10000 Hoechst 33342 dye (Invitrogen, 
Eugene) for 15 min and then subjected to Opera fluorescence confocal microscope System (Perkin 
Elmer) using 40x magnification for localization analysis of GnTI and UDP-GlcNAc transporter. 
Constant imaging parameters were used for acquiring images within the same set of experiments. 
ImageJ 1.47 (NIH) was used to crop representative areas and to produce the final figures. 
7.2.4. Cell culture and fed-batch process 
Fed-batch culture was carried out using the cell lines A, A-M18, A-E15, B, B-M4, B-M7 and B-
E15 under the cultivation conditions as described in Chapter 6. Proprietary feed (10% of the initial 
culture volume) was added to the culture on days 2, 5, 7, 9 and 11. Glucose concentration was 
adjusted to 33mM on day 5 and to 50mM on days 9 and 11. Similar as described in Chapter 6, cell 
growth, metabolism and mAb production was monitoring during the fed-batch process on days 2, 5, 
7, 9, 11 and 14, and intracellular nucleotide sugar quantification was carried out on days 2, 5, 9 and 
11. Cell culture was harvested and mAb glycoprofiling was performed on day 14. 
7.2.5. mAb purification and glycoprofiling 
mAb purification was carried out as described previously (Chapter 6). Glycoprofiling of the purified 
mAb was performed using the same method as reported in (Fan et al. 2014). 
7.2.6. Statistical analysis of glycoform distributions 
Differences in the expression level of GnTI or UDP-GlcNAc transporter and in glycoforms of mAb 
produced among original and engineered cell lines were evaluated statistically. Statistical 
significant difference (pANOVA<0.05) was evaluated by One-way ANOVA with Dunnett post hoc 
pairwise comparison test using GraphPad Prism 5. 
7.2.7. Nucleotide sugar analysis 
Nucleotide sugar analysis was carried out as previously described using acetonitrile extraction and 
high-performance anion-exchange (HPAEC) HPLC (Fan et al. 2014; Jimenez Del Val et al. 2013). 
7.3. Results  
Improving mAb productivity without reducing the maturation of N-glycosylation is one of the 
major concerns during cell line and process development. Therefore, it is extremely valuable to 
explore efficient ways of improving the maturation of glycans, in particular, reducing high mannose 
forms and increasing GlcNAc and Gal occupancy of the glycans. Here, we overexpress either GnTI 
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or UDP-GlcNAc transporter in two mAb producing cell lines and investigate the impact on the fed-
batch culture performance, mAb productivity and glycosylation. 
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Figure 1. Construction of Plasmids. PacI/Nt.BbCI digestion of USER cloning-compatible version of 
SLXplasmid_0191 or 0192 is presented in A. USER assembly of DNA fragments containing functional 
elements for p1 (SLX0191_PuroR_EF1α_FLAG-tag::UDP-GlcNAcTransporter_IRES_eGFP) , p2 
(SLX0192_HygR_EF1α_GnTI::HA-tag_IRES_mCherry), p3 (SLX0191_PuroR_EF1α_UDP-
GlcNAcTransporter_IRES_eGFP) and p4 (SLX0192_HygR_EF1α_ GnTI _IRES_mCherry) are illustrated in 
B, C, D and E. 
 
Figure 2. Analysis of intracellular GnTI and UDP-GlcNAc overexpression. (A) Quantification of 
intracellular GnTI and UDP-GlcNAc transporter levels in the parental (A and B) and engineered (A-M18, A-
E15, B-M4, B-M7 and B-E15) cell lines by western bolt. The criteria for significant differences are: * for 
p<0.05, ** for p<0.01 and *** for p<0.001. (B) Subcellular localization of the overexpressed GnTI in cell 
line B-Mt. HA-tagged GnTI (Red); GM130 Golgi marker (Green); Co-localization (Yellow).  (C) 
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Subcellular localization of the overexpressed UDP-GlcNAc transporter in cell line B-Et. FLAG-tagged UDP-
GlcNAc transporter (Red); GM130 Golgi marker (Green); Yellow: Co-localization.  
7.3.1. Plasmids and cell line engineering 
Cell lines A and B were tranfected using the plasmids constructed by USER cloning (Figure 1). 
Various engineered cell lines that overexpressed GnTI or UDP-GlcNAc transporter were generated 
and isolated by single cell sorting. According to the strength of florescent signals, 8 cell lines were 
selected for further investigation (Table I). 
Table I. Engineered cell lines used in the study. 
Cell line Plasmid used Overexpression Florescent signal 
A-M18 p4 GnTI mCherry 
A-E15 p3 UDP-GlcNAc transporter eGFP 
B-M4 p4 GnTI mCherry 
B-M7 p4 GnTI mCherry 
B-E4 p3 UDP-GlcNAc transporter eGFP 
B-Mt p2 GnTI:HA mCherry 
B-Et p1 FLAG: UDP-GlcNAc transporter eGFP 
In order to quantify the overexpression levels, western blot analysis of GnTI and UDP-GlcNAc 
transporter on the selected cell lines were carried out. As shown in Figure 2A, cell lines A-M18, B-
M4 and B-M7 have 2-fold overexpression of GnTI in comparison to their parental cell line. 
Additionally, overexpression of UDP-GlcNAc transporter with statistical significance in cell lines 
A-E15 and B-E4 can also be confirmed. Figures 2B and 2C indicate that the overexpressed GnTI 
and UDP-GlcNAc transporter are correctly localized in Golgi, and thus they are considered to 
properly function in the cells. It is also necessary to mention that no change in UDP-GlcNAc 
transporter expression can be observed when overexpressing GnTI in both A and B cell lines and 
vice versa. This implies that there are no regulatory interactions between GnTI and UDP-GlcNAc 
transporter in our cells. 
7.3.2. Fed-batch performance and mAb production  
Culture performance and mAb productivity of culture processes with eight different cell lines (A, 
A-M18, A-E15, B, B-M4, B-M7 and B-E4) are shown in Figure 3. Minor clone specific effect can 
be observed in A-M18 and A-E15 cell lines. They have faster cell growth, increased integral of 
viable cells (IVC), similar specific productivity (qp) of mAb and comparable metabolic profile of 
lactate and NH4
+
 in comparison with their parental cell line. On the other hand, cell lines that 
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engineered from cell line B shows larger variations of clone specific effect. Cell line B-M4 has 
comparable qp as cell line B, but dramatically higher IVC. In contrast to that, cell line B-M7 has 
comparable cell growth as cell line B, but lower qp. Additionally, when comparing to cell line B, B-
E4 cell line shows earlier onset of cell death and reduced IVC and qp. This may be attributed to 
higher lactate accumulation during the cell culture that inhibits the cell growth and threatens the 
culture longevity.  
 
Figure 3. Comparison of fed-batch cultures of the parental (A and B) and engineered (A-M18, A-E15, B-M4, 
B-M7 and B-E15) cell lines. Viable cell density, viability and IgG titer vs. integral of viable cells (IVC) are 
presented in A, B and C, respectively. Variations of lactate and ammonia concentrations during the cell 
culture are shown in D and E. The error bars indicates the standard deviation of duplicate experiments.  
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7.3.3. Glycosylation profiles of mAbs produced from engineered and parental cell lines 
The glycosylation profiles are shown in Figure 4. Cell line A-M18 presented lower high mannose 
forms (Man9, Man7, Man6, Man5 and Mannose core) and higher A1G0, G0 and G0F forms than 
cell line A. Especially, the reduction of Man5 and the elevation of A1G0 is in accordance with the 
expected function of GnTI overexpression. On the other hand, cell line A-E15, which has an 
overexpression in UDP-GlcNAc transporter, showed no apparent decreasing in Man5 and 
increasing in A1G0. This implies that overexpression in UDP-GlcNAc transporter may not facilitate 
the GlcNAc addition reactions in the glycan maturation process in cell line A. 
 
Figure 4. Intracellular nucleotide sugar analysis. The intracellular levels of UDP-GlcNAc and UDP-Gal in 
the parental (A and B) and engineered (A-M18, A-E15, B-M4, B-M7 and B-E15) cell lines are shown.  
Similar as cell line A, increased A1G0 and decreased Man5 glycoforms can be observed when 
overexpressing GnTI in cell line B (B-M4 and B-M7 cell lines). This once again indicated that 
increase GnTI availability can slightly relieve the limitation of glycan maturation at the stage from 
Man5 to A1G0 glycoforms. However, no apparent changes in the major glycoforms observed 
(Man5, A1G0, A1G0F, G0F and G1F) when overexpressing UDP-GlcNAc transporter in cell line B 
(B-E4 cell line). 
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7.3.4. Intracellular nucleotide sugar metabolism 
Nucleotide sugars are synthesized in the cytosol and transported into Golgi to be able to act as 
donors for glycan elongation reaction. The levels of the intracellular nucleotide sugars are therefore 
strongly associated with glycosylation. As shown in Figure 5, increasing accumulation of UDP-
GlcNAc during the cell culture can be observed in both cell lines A and B. In general, all 
engineered cell lines displayed lower levels of intracellular UDP-GlcNAc than that in their parental 
cell lines from day 5 to day 11. In addition, A-M18 and A-E15 cell lines showed higher 
accumulation of UDP-Gal, whereas B-M4, B-M7 and B-E4 presented lower intracellular 
concentration of UDP-Gal, in comparison with the corresponding parental cell line from day 5 to 
day 11. 
 
Figure 5. Glycoprofiles of mAbs produced from the cell cultures of the parental (A and B) and engineered 
(A-M18, A-E15, B-M4, B-M7 and B-E15) cell lines. 
7.4. Discussion 
In this study, we have established a number of mAb production cell lines with GnTI or UDP-
GlcNAc transporter overexpressed stably, using random integration approaches. The resulting 
engineered cell lines have been tested in fed-batch culture in order to evaluate the impact on 
glycosylation patterns.  
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Golgi GnTI activity is essential for adding a GlcNAc residue to Man5 glycan in N-glycosylation 
process. A number of studies demonstrated that knock-out GnTI inhibits glycan maturation process 
and generates high mannose structure, mainly Man5 glycan (Sealover et al. 2013; Zhong et al. 
2012). In contrast to that, a reduction of Man5 should therefore be expected, when GnTI is 
overexpressed. This is due to the fact that the abundance of glycosyltransferase relative to the 
specific productivity of the recombinant protein can be one of the bottlenecks that prevent glycan 
maturation.  
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Figure 6. Average GlcNAc and galactose occupancy on glycans.  The GlcNAc and Gal occupancy was 
calculated as described in  (Fan et al. 2014). Statistical significance criteria: * for p<0.05, ** for p<0.01 and 
*** for p<0.001. 
Another possible bottleneck that can limit the glycan maturation is the availability of nucleotide 
sugars within the Golgi apparatus. This may be affected by the efficiency of nucleotide sugars 
synthesis in cytosol (Kochanowski et al. 2008) and the capability of transfer these species into the 
Golgi apparatus (Weikert et al. 1999; Wong et al. 2006). It has been reported previously that UDP-
GlcNAc transporter can not only transport UDP-GlcNAc but also UDP-Gal into Golgi apparatus 
(Maszczak-Seneczko et al. 2011). In order to reduce Man5, increase GlcNAc and probably also Gal 
occupancy, overexpression of UDP-GlcNAc transporter was anticipated to be a feasible approach. 
In consistency with our hypothesis of the effect of GnTI overexpression on mAb glycosylation, we 
found that overexpression of GnTI in both A and B cell lines statistically significant increase 
GlcNAc occupancy (Figure 6). Especially cell lines A-M18 and B-M4, comparing to their parental 
cell lines, presented an about 4% increase in GlcNAc occupancy despite their relatively higher 
average qp (Figure 7). This indicates that the increase in GlcNAc occupancy is purely attributed to 
the increased expression of GnTI in Golgi that transfer GlcNAc residues to Man5 glycans more 
efficiently. Additionally, the increasing in average qp in A-M18 cell line may overload the capacity 
of galactosylation and thus decreasing Gal occupancy in comparison with cell line A.  
 
Figure 7. Relationship between average specific productivity of cell lines during the fed-batch culture and 
average GlcNAc and galactose occupancy. 
On the other hand, the higher GlcNAc and GalNAc occupancy in cell line B-M7 may be a 
combinatory effect of increased GnTI expression and decreased qp. It is also worth to mention that 
the increase in GlcNAc occupancy in A-M18, B-M4 and B-M7 cell lines although was mainly as a 
result of decrease Man5, did not change the fucosylation level of the produced mAb. The reduced 
Man5 was mainly turn into non-fucosylated A1G0 glycoforms in consequence of a limitation in 
fucosylation capacity. 
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Overexpression of UDP-GlcNAc transporter did not show the expected effect on glycosylation as 
described above. Both A-E15 and B-E4 cell lines present no statistically significant increase in 
GlcNAc occupancy. The increase in Gal occupancy in B-E4 cell line is as a result of clone specific 
effect that reduced the average qp of the cells (Figure 7). Our data suggest that the capacity of UDP-
GlcNAc transport is not a limitation factor that prevents glycan maturation in both cell lines A and 
B. The availability of UDP-GlcNAc is well-matched with GnTI activity in both cell lines.  
Additionally, the concentrations of intracellular nucleotide sugars UDP-GlcNAc and UDP-Gal were 
in consistency with the levels of them consumed by glycosylation processing. In general, the 
engineered cell lines with increased GlcNAc and Gal occupancy displayed lower accumulation of 
UDP-GlcNAc and UDP-Gal concentration. This suggests that the biosynthesis of UDP-GlcNAc and 
UDP-Gal are independent processes and overexpression of GnTI or UDP-GlcNAc transporter have 
no regulation effect on their biosynthesis. 
In conclusion, overexpression of GnTI in mAb producing cell lines generate less Man5 and higher 
GlcNAc occupancy. However, overexpression of UDP-GlcNAc transporter cannot increase 
GlcNAc occupancy in our cell lines. The clone specific effect that affects the average specific 
productivity of mAb is a critical issue that can influence the maturation of glycans.  
One of the perspectives in cell line engineering is to minimize clone specific effect, for example 
using site-specific integration instead of random integration. With recent development of genome 
editing tools, including CRISPR/Cas9, TALEN, ZFN system, to generate gain/enhance-of-function 
phenotype without inducing clone specific effect became possible. Future cell line development in 
modulating glycosylation towards more matured glycans can be done by further exploring the effect 
of combinatory overexpression of GnT1 and GlcNAc and overexpression of other glycotransferases, 
for example galactosyltransferase. 
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Chapter 8 Conclusion and future perspectives 
In order to explore potentials and develop novel strategies to control and optimize N-glycosylation 
of CHO-derived recombinant monoclonal antibody (mAb), we conducted the research of CHO cell 
bioprocessing using systems biology approaches, where better understanding of interrelations 
among physiological, metabolic and proteomic status of CHO cells during manufacturing processes 
and the quantity and quality of produced mAbs was achieved. 
Two major strategies were tested to modulate N-glycosylation of mAb. First strategy was to 
optimize culture media and improve upstream process. Second strategy was to genetically modified 
glycosylation genes in CHO cells. Although the effect and efficiency were cell line dependent, both 
strategies were shown to work in different study cases. 
A number of important findings were demonstrated using the first strategy: (1) Balance of glucose 
and amino acid concentration in the culture can affect specific consumption rate of amino acid and 
glucose in CHO cells. Elevated Man5 glycan structure was in association with high specific amino 
acid consumption, whereas more matured glycans can be produced when high specific glucose 
consumption rate was achieved. (2) Reduced specific productivity of mAb (qp), as a result of 
glucose starvation at stationary phase of fed-batch culture, can improve the level of glycan 
maturation. (3) Feeding galactose as feed additives can increase the level of galactosylation. (4) 
Increased cultivation duration  can cause elevated Man5 glycan. 
The second strategy was also shown valuable results in controlling N-glycosylation: (1) 
Overexpression of N-acetylglucosaminyltransferase I (GnTI) could also increase GlcNAc and/or 
Gal occupancy of mAb for certain cell line. (2) Overexpression of N-acetylglucosamine (GlcNAc) 
transporter in CHO cells, which was expected to increase UDP-GlcNAc and UDP-Gal 
transportation from cytosol to Golgi apparatus do not seem to improve maturation of glycans for the 
cell lines tested. 
Integrating systems biology with CHO cell bioprocessing (i.e. linking various omics data, 
cultivation process data and protein quality data together from more cell lines) in the future will be 
an important approach of exploring possible bottlenecks in the glycosylation process in different 
cell lines. By doing that, both the established and new approaches that could modulate N-
glycosylation toward more desired patterns can be developed to targeting different cell lines with 
better specificity and higher efficiency.  
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Appendix I: Supporting information of Chapter 3 
 
Figure S1. Additional data for comparison of five fed-batch cultures with different cell lines and cultivation 
conditions. (A) Viability, (B)  Integral of viable cells (IVC),  (C) IgG titer,  (D) Osmolarity, (E) pH, (F) 
Specific IgG production rate (PCD) are shown. Specific consumption rates of glucose (G), glutamine (H) and 
glutamate (I) are also shown. Specific lactate (J) and ammonia (K) production rates are presented. 
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Figure S2. Western blot analysis of GnT1 and UDP-GlcNAc transporter in this study. 
  
Figure S3. Average specific IgG productivity. Linear regressions were performed on raw data grouped by 
cell line. 
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Figure S4. HPLC Chromatogram of instant-AB labeled glycoprofiling.    
Table SI. Amino acid composition of 4384 IgG.  
4384 IgG % 
Ser 13.16 
Val 8.62 
Thr 8.17 
Leu 8.02 
Lys 6.81 
Pro 6.51 
Gly 6.20 
Glu 4.99 
Gln 4.99 
Ala 4.69 
Asn 4.39 
Tyr 4.39 
Asp 3.78 
Phe 3.18 
Arg 2.57 
Cys 2.42 
Ile 2.12 
His 2.12 
Trp 1.82 
Met 1.06 
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Appendix II: Supporting information of Chapter 4 
Table SI. Detailed cultivation parameters. 
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Figure S1 Viable cell density of all cell cultures with feed additives. 
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Figure S2 IgG titer of all cell cultures with feed additives. 
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Figure S3 Detailed glycoprofiles of all cell cultures. 
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Figure S4 Spectrum and chromatogram peak assignment. (A) Peak assignment of intact mass analysis 
spectrum; (B) Peak assignment of cation exchange chromatogram; (C) Peak assignment of glycoprofiling 
chromatogram. 
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Appendix III: Supporting information of Chapter 6 
 
Figure S1. Chromatogram of CEX and assignment of charge variants 
Table S1-11 can be found in an excel file on a webpage: 
https://www.dropbox.com/sh/d56e21intwzq3pf/AACJQtgM81fu5aUMWnLXpSjza?dl=0 
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Appendix IV: Supporting information of Chapter 7 
Table S1 Primers used in this study 
Primer name Description Sequences Tm Template p 1 p 2 p 3 p 4 
EYF-1 eGFP_USER_FW  
ATTCCGAUCGC
CACCATGGTGA
GCAAG 
62,78 peGFP-1  739bp   739bp   
EYF-2 eGFP_USER_RW  
AGCTTAAUCTT
GTACAGCTCGT
CCATGCC  
60,58 peGFP-1  739bp   739bp   
EYF-3  FLAG-tag_UDPGlcNAcTrans_USER_FW  
ACGTCGCUATG
GACTACAAAGA
CCATGACGG 
60,65 
pUC57_FLAG::UDPGl
cNAcTransporter  
1063bp       
EYF-4  FLAG-tag_UDPGlcNAcTrans_USER_RW  
ATCGCACUCTA
TGCTTTAATGGG
ATTTCCTGC  
59,64 
pUC57_FLAG::UDPGl
cNAcTransporter  
1063bp       
EYF-5  IRES_USER_FW 
AGTGCGAUAAT
TCCGCCCCTCTC
CCC 
63,21 pIRES-DHFR  612bp 612bp     
EYF-6  IRES_USER_RW 
ATCGGAAUTTA
TCATCGTGTTTT
TCAAAGGAA 
58,99 pIRES-DHFR  612bp 612bp 612bp 612bp 
EYF-7  GnTI_HA-tag_USER_FW  
ACGTCGCUATG
CTGAAGAAGCA
GTCTGCA 
58,48 pUC57_GnTI::HA    1387bp     
EYF-8  GnTI_HA-tag_USER_RW 
ATCGCACUCTA
AGCGTAATCTG
GAACATCG 
57,37 pUC57_GnTI::HA    1387bp     
EYF-9  mCherry_USER_FW  
ATTCCGAUCGC
CACCATGGTGA
GCAAG 
62,78 pmCherry-N1    734bp   734bp 
EYF-10  mCherry_USER_RW  
AGCTTAAUCTA
CTTGTACAGCTC
GTCCATGCC 
63,06 pmCherry-N1    734bp   734bp 
EYF-11  UDPGlcNAcTrans_USER_FW_2 
ACTTGCGUATG
TCCGCCAACCT
AAAATATC 
58,08 
pUC57_FLAG::UDPGl
cNAcTransporter  
    997bp   
EYF-12  UDPGlcNAcTrans_USER_RW_2 
ACCAGGCUCTA
TGCTTTAATGGG
ATTTCCTGC  
59,64  
pUC57_FLAG::UDPGl
cNAcTransporter  
    997bp   
EYF-13  IRES_USER_FW_2 
ACCAGGCUAAT
TCCGCCCCTCTC
CCC 
63,21 pIRES-DHFR      612bp 612bp 
EYF-14  GnTI_USER_FW_2 
ACTTGCGUATG
CTGAAGAAGCA
GTCTGCA 
58,48  pUC57_GnTI::HA        1360bp 
EYF-15  GnTI_USER_RW_2 
ACCAGGCUCTA
ATTCCAGCTAG
GATCATAGCC 
59,06 pUC57_GnTI::HA        1360bp 
 
Table S2 Plasmid and PCR template used in this study 
Template  Functional elements Source 
peGFP-1  eGFP Clontech 
pIRES-DHFR  IRES (Lund et al. 2014) 
pmCherry-N1  mCherry Clontech 
pUC57_FLAG::UDPGlcNAcTransporter  
UDPGlcNAcTransporter ± FLAG-
tag GenScript 
pUC57_GnTI::HA  GnTI ± HA-tag GenScript 
SLXplasmid_0191 SLXplasmid_0191 backbone Selexis 
SLXplasmid_0192 SLXplasmid_0192 backbone Selexis 
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Figure S1. Construction of USER compatible plasmids 
 
Figure S2. Western blot analysis of GnTI and UDP-GlcNAc transporter of cell lines selected in this study  
